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Increasing evidence supports a strong relationship between tumor hypoxia and tumor 
aggressiveness, poor outcome and resistance to therapies. Tumor hypoxia results from the negative 
balance between the oxygen demands of the tissue and the capacity of the neovasculature to deliver 
satisfactory oxygen provisions. A plethora of treatments have been proposed recently to overcome 
specifically the hypoxic burden (photodynamic therapy, hyperoxic gas breathing during radiotherapy, 
hypoxia sensitive theƌĂƉĞƵƚŝĐƐ ? ) ? aimed to improve the results of oncotherapy. However, the lack of 
suitable methods to assess tumor hypoxia in the clinic, makes it not possible to identify a priori those 
tumors potentially sensitive to the hypoxic directed treatment and, thus, those patients that could 
benefit from these novel therapies. Magnetic Resonance (MR) methods are well endowed to fulfill 
these needs. On these grounds, the aim of this thesis is to develop and implement novel strategies to 
measure tumor hypoxia using MR methods. To this end, we followed two independent approaches; 
1) The development and implementation of novel exogenous contrast agents revealing tissue 
hypoxia and 2) The development and implementation of new and advanced methods of endogenous 
imaging contrast sensitive to the environmental oxygen tension. 
In our first approach, we synthesized and characterized new 2-nitromidazole derivatives as 
exogenous hypoxia markers. Their potential use was investigated both in vitro and in cell cultures, 
and the results obtained compared with those generated by commercial hypoxia markers. We 
characterized the main determinants of the metabolism of nitroimidazole derivatives proposing a 
new mechanism for their bioreduction and sensitivity to hypoxia, implementing a new method to 
obtain hypoxia maps from the bioreduction of nitroimidazoles as detected non invasively by 1H 
Magnetic Resonance Spectroscopy Imaging (MRSI). 
In our second approach, we exploited the sensitivity of the relaxation times of endogenous tissue 
water to physiological oxygen concentrations. The paramagnetic nature of oxygen, induced 
appreciable, concentration dependent, T1 shortening in vivo, as revealed by T1 weighted MRI, an 
approached named Tissue Oxygenation Level Dependent (TOLD). Based on these images, we 
designed and tested a new MRI methodology to identify those tumors that could benefit from a 
hypoxia directed therapy as breathing gas mixtures with high oxygen content. Taken together, our 
results provide a new frame for the non invasive measurement of tumor hypoxia by Magnetic 
Resonance methods. 
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Cada día más evidencias apoyan la existencia de una fuerte relación entre hipoxia y  agresividad  
tumoral, así como con un peor pronóstico y mayor resistencia a la terapias oncogénicas. La hipoxia 
tumoral resulta del balance negativo entre las demandas tisulares de oxígeno y la capacidad de la 
neovasculatura para satisfacer dichas necesidades. Recientemente, se ha propuesto toda una plétora 
de tratamientos específicamente dirigidos a superar el daño originado por la hipoxia (terapia 
fotodinámica, respiración de gases con alto contenido en oxígeno durante la radioterapia, fármacos 
ƐĞŶƐŝďůĞƐĂůĂŚŝƉŽǆŝĂ ? )ĐŽŶĞůŽďũĞƚŝǀŽĚĞŵĞũŽƌĂƌůŽƐƌĞƐƵůƚĂĚŽƐĚĞůĂŽŶĐŽƚĞƌĂƉŝĂ ?^ŝŶĞŵďĂƌŐŽ ?ůĂ
falta de una metodología clínica para evaluar la hipoxia tumoral hace imposible detectar, a priori, 
aquellos tumores potencialmente sensibles a los tratamientos dirigidos especificamente a la hipoxia 
y, por lo tanto, aquellos pacientes que específicamente se podrían beneficiar de estas nuevas 
terapias. Los métodos de Resonancia Magnética (RM) se presentan como una buena alternativa para 
realizar dicha tarea. En base a esto, el objetivo de esta tesis es el desarrollo y la implementación de 
nuevas estrategias para medida de la hipoxia tumoral empleando métodos de RM. Con este objetivo, 
se emplearon dos aproximaciones independientes: 1) Desarrollo e implementación de nuevos 
agentes de contraste exógenos para la mediada de hipoxia tisular y 2) Desarrollo e implementación 
de nuevos y avanzados métodos sensibles a la tensión de oxígeno utilizando un  contraste endógeno.  
En nuestro primer enfoque, sintetizamos y caracterizamos nuevos derivados de 2-nitroimidazol como 
marcadores de hipoxia exógenos. Su potencial aplicación se investigó in vitro y en cultivos celulares, 
y los resultados obtenidos se compararon con los generados por marcadores comerciales de hipoxia. 
Se caracterizaron los factores principales del metabolismo de los derivados de 2-nitroimidazol, 
proponiendo un nuevo mecanismo para su bioreducción y sensibilidad a hipoxia. Se implementó un 
nuevo método para la obtención de mapas de hipoxia basados en la bioreducción de 2-
nitroimidazoles detectada de manera no invasiva mediante Imagen Espectroscópica de Resonancia 
Magnética de 1H.  
En nuestra segunda aproximación, utilizamos la dependencia de los tiempos de relajación del agua 
tisular con la concentración fisiológica de oxígeno. La naturaleza paramagnética de la molécula de 
oxígeno induce acortamientos del T1 in vivo apreciables y dependientes de la concentración de 
oxígeno, según se observa en la Imagen de Resonancia Magnética (IRM) pesada en T1, en una 
aproximación denominada Nivel Dependiente de Oxigenación Tisular. Basándonos en estas 
imágenes, se diseñó y se probó una nueva metodología de IRM para identificar aquellos tumores que 
podrían beneficiarse de una terapia dirigida a la modulación de la hipoxia, como respirar mezclas de 
gases con alto contenido en oxígeno. En conjunto, nuestros resultados proporcionan una nueva 
metodología para la medida no invasiva de la hipoxia tumoral por métodos de RM.  
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19F RI: 19F Retention Index.  
ADC: Apparent Diffusion Coefficient. 
ANOVA: analysis of variance. 
ARDVARC: Alternating Relaxation Delays with Variable Acquisitions for Reduction of Clearance 
effects. 
ARNT (HIF-1E): Aryl hydrocarbon Receptor Nuclear Translocator. 
ATP: Adenosine-5'-triphosphate. 
B0: Magnetic Field. 
BOLD: Blood Oxygen Level Dependent. 
CHO: Chinese hamster ovary cells. 
CPMG: Carr Purcell Meiboom Gill. 
CREB: cyclic AMP-response-element-binding protein. 
Cu-ATSM: Copper diacetylbis-N(4)-methylthiosemicarbazone. 
DCE: Dynamic Contrast Enhanced. 
DMEM: Dulbecco's Modified Eagle Medium. 
DTI: Diffusion Tensor Imaging. 
DTNB: 5,5'-dithiobis(2-nitrobenzoate).  
DWI: Diffusion Weighted Imaging. 
EF5: 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide.  
EPI: Echo Planar Imaging. 
EPR: Electron Paramagnetic Resonance. 
FBS: Fetal Bovine Serum. 
FIH: Factor Inhibiting HIF-1. 
FOV: Field Of View. 
FREDOM: Fluorocarbon Relaxometry using Echo planar imaging for Dynamic Oxygen Mapping.  
GEMS: Gradient Echo Multiple Slice. 
GR: Glutathione Reductase. 
GSH: Reduced glutathione. 
GSSG: Oxidized glutathione. 
Hb: Hemoglobin. 
HFB: Hexafluorobenzene.  
HIF-1: Hypoxia-Inducible Factor-1.  
HMDSO: Hexamethyldisiloxane.  
HRE: Hypoxia-Response Element.  
HR-MAS: High Resolution Magic Angle Spinning. 
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ISUCA: (+/-)2-(Imidazol-1-yl)Succinic Acid. 
MISO: Misonidazole.  
Misonidazole: (RS)-1-Methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol. 
MR: Magnetic Resonance. 
MRI: Magnetic Resonance Imaging. 
MRS: Magnetic Resonance Spectroscopy. 
MRSI: Magnetic Resonance Spectroscopy Imaging. 
Mtx: acquisition matrix. 
NADH: Nicotinamide Adenine Dinucleotide. 
NADP+: E-Nicotinamide Adenine Dinucleotide Phosphate Oxidized. 
NADPH: E-Nicotinamide Adenine Dinucleotide Phosphate Reduced. 
NF-kB: Nuclear Factor-kB.  
NISUCA: Dimethyl 2-(2-Nitro-1H-imidazol-1-yl)succinate. 
NIMAC: Methyl 2-(2-nitro-1H-imidazol-1-yl)acetate. 
NIR: Near Infrared. 
NPSH: Nonprotein Sulfhydryls. 
OMRI: Overhauser-enhanced MRI. 
P450ase : NADPH:Cytochrome-P450 reductase. 
PCr: Phosphocreatine. 
PET: Positron Emission Tomography.  
PFC: Perfluorocarbon. 
PHD: Prolyl hydroxylase-domain protein. 
Pi: Inorganic Phosphate. 
Pimonidzole: [(2-nitro-1H-imidazol-1-yl)methyl]-1-piperidineethanol (Ro 03-8799). 
PISTOL: Proton Imaging of Siloxanes to map Tissue Oxygenation Levels. 
PLSD: Protected Least Significant Difference. 
PTSA: para-Toluenesulfonic acid. 
PRESS: Point Resolved Spectroscopy.  
pO2: Partial pressure of oxygen. 
pVHL: Von Hippel WLindau tumor-suppressor protein. 
RARE: Rapid Acquisition Relaxation Enhancement. 
RIF: Radiation Induced Tumors. 
ROS: Reactive Oxygen Species. 
SE: Standard Error. 
SEMS: Spin Echo Multiple Slice. 
 25 
 
A
b
b
re
via
tio
n
s 
&
 A
cro
n
y
m
s 
SI: Signal Intensity. 
SOD: Superoxide Dismutase. 
SPECT: Single-Photon Emission Computed Tomography. 
SNR: Singal to Nosie Ratio.  
T: Temperature. 
T1W: T1 weighted images. 
T2W : T2 weighted images. 
T2*W: T2* weighted images. 
TBAI: Tetrabutylammonium Iodide.  
TE: Echo Time. 
TNB: 2-nitro-5-thiobenzoate. 
TOLD: Tissue Oxygen Level Dependent.  
TR: Repetition Time 
TSP: Trimethylsilyl -2,2´,3,3´tetradeutero-propionic acid. 
VAPOR: Variable Pulse Power and Optimized Relaxation Delays.  
VDT: Volume Doubling Time. 
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The extracellular space of tissues is located between the cellular architectures and the capillary 
network providing a vital space for intercellular communication and regulatory metabolic 
interactions (Figure 1). The biochemical profile of this compartment modulates many vital 
intracellular functions including differentiation (47), tissue regeneration (222), angiogenesis (139), 
metastasis (33), proliferation (160) and apoptosis (69) or necrosis (195), among others. The 
extracellular millieu is characterized by a collection of environmental properties, such as pH, partial 
pressure of oxygen (pO2), ionic composition and diffusion. These are significantly different from 
those of the intracellular or vascular spaces, configuring in this way a physiologically distinct 
compartment. Alterations in the environmental properties of tissues are known to occur very early 
during disease development, providing precious information for the diagnosis, prognosis and therapy 
assessment of the most prevalent and morbid pathologies in developed countries, with particular 
emphasis in cancer and ischemic episodes (61,92,132).  
The biochemical properties of the microenvironment result from the balance between the cellular 
uptake and metabolism of substrates as glucose and oxygen from the capillaries, and the removal of 
waste products as lactate and H+ through the tissue microvasculature (Figure 1a). Intracellular 
oxidative metabolism leads simultaneously to the production of freely diffusing CO2 and H2O (in fast 
equilibrium with HCO3
- and H+ through the carbonic anhidrase enzyme). Reductions in glucose or 
oxygen delivery either by systemic limitations or inadequate performance of the local capillary 
network, result in extracellular lactate and proton accumulation, two conditions commonly found 
during the early development of most pathologies, including tumors (Figure 1b). On these grounds, 
non invasive imaging of the microenvironment has gained substantial scientific and clinical interest in 
the last decades (63,88,190). Several techniques have been used for this purpose: positron emission 
tomography (PET) (13,189,212), single photon emission computed tomography (SPECT) (16,56,158), 
immunohistochemistry (114)... Among them, Magnetic Resonance (MR) methods present several 
favorable properties as noninvasiveness, high spatial and temporal resolution, good contrast 
between the different tissues and use no ionizing radiation, making the approach particularly 
suitable to investigate the properties of the extracellular microenvironment.  
1.1. Hypoxia 
 
The quantitative measurement of the oxygen tension in healthy and diseased tissues represents a 
long-standing endeavor of medicine and biology since Carl Scheele, Joseph Priestly and Antoine 
Lavoisier discovered molecular oxygen (48). The concept of hypoxia indicates oxygen shortage. In 
normal tissues as heart or brain, hypoxia may be attributed to ischemia, where the delivery of 
oxygen is insufficient to maintain normal physiological function. Hypoxia may occur due to a local 
decrease in vascular flow or to insufficient hemoglobin saturation. For instance, an acute myocardial 
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infarct will result in rapid oxygen depletion and loss of mechanical function. It has been shown, as 
expected, that the effects of hypoxia are much more rapid in the beating heart than in the arrested 
heart, and indeed, the rate loss of developed pressure is directly proportional to decrease in partial 
pressure of oxygen (pO2) (225). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The extracelular microenvironment of tissues.  
The extracellular microenvironment of tissues is located between the vascular and intracellular spaces. a) 
Under normal conditions it is characterized by physiological oxygen tension, and relatively low concentrations 
of lactate and H
+
 due to the efficient perfusion and removal of metabolic products by the microvasculature. b) 
Reduced performance of the microvasculature (purple) under most pathological situations results in, reduced 
oxygen tensions, and concomitant lactate and H
+
 accumulation in the diseased extravascular space (brown). 
Magnetic resonance imaging has progressed from conventional T2 weighted anatomical images (c) to molecular 
images revealing particular properties of the extracellular environment as pH in the brain of a rata bearing a C6 
tumor (d). In this work we extend these approaches to the imaging of oxygen tensions. 
 
1.1.1. Tumor hypoxia 
 
The definition of hypoxia in tumors may become far more complex, since neoplastic tissue is 
aberrant with no particular normal function, yet the well documented ability to grow and adapt to 
stress. Low oxygen levels are a recognized prognostic marker in oncology, with numerous reports 
linking tumoral hypoxia to therapy failure and poor patient outcome (196). To our knowledge, Gray 
et al. (65) were the first to provide evidence that some tumors are hypoxic in vivo. In particular, they 
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showed that human bronchial carcinomas with necrotic areas, located approximately 150 µm away 
from the nearest blood vessel, had lower oxygen tension than the surrounding tissues. It was not 
until 1988, however, that a direct relationship between tumor hypoxia and treatment failure was 
reported (59). Lymph nodes from squamous cell carcinoma of the head and neck showed significant 
differences in the median pO2 (as investigated with polarographic electrodes) between tumors 
responding and not responding to radiotherapy. Since then, multiple studies have confirmed that 
pO2 constitutes a crucial prognostic marker of patient outcome and therapy success 
(50,145,165,196), including chemotherapy (66,209), radiotherapy (66,72), photodynamic therapy 
(207,209) and surgical tumor resection (78). Indeed, a threefold increase in radio-resistance may 
occur when cells are irradiated under hypoxic conditions compared to cells irradiated under 
normoxic conditions (pO2 > 15 Torr), in a single radiation dose (65).  
In addition to increased resistance to therapies, a direct relationship has been proven between 
hypoxia and aggressiveness in different tumor types (50,80,208), suggesting that hypoxia constitutes 
a universally negative factor in the prognosis and treatment of neoplastic diseases (145,165). As a 
consequence, a collection of adjuvant therapeutic interventions related to hypoxia have been 
proposed in recent decades to improve the therapeutic outcome of cancers. These include i)  “ĚŽƐĞ-
ƉĂŝŶƚŝŶŐ ? ?ďŽŽƐƚĞƌƌĞŐŝŵĞŶƐĂŶĚŝŶƚĞŶƐŝƚǇŵŽĚƵůĂƚĞd radiation therapy (IMRT) (55,117,119,198,224), 
ii) administration of adjuvant hypoxic cell selective cytotoxins, even though clinical trials with 
tirapazamine were discontinued and iii) breathing hyperoxic gas mixtures. Indeed, many clinical trials 
have explored oxygen (O2), carbogen (mixture of 95 % O2 and 5 % CO2) or hyperbaric gas breathing 
(154). The meta analysis by Overgaard et al. (152,153) of some 10,000 patients indicated a clinical 
advantage for manipulating tumor hypoxia. However, the overall conclusion was that there was a 
pressing need to identify those tumors (viz. patients) that would actually benefit from it. On these 
grounds, more precise and robust measurements of the oxygen levels in vivo would allow a better 
selection of patients responding positively to hypoxia-directed treatments and a more adequate 
understanding of the significance of tumor oxygen levels on the outcome of the different therapies.  
It is relevant to point out here that no single pO2 threshold can be widely applied to determine the 
limit for hypoxic and normoxic areas in all tissues. In other words, hypoxia does not have an absolute 
definition and does not entail a universal threshold. Normal tissue shows a typical Gaussian 
distribution of oxygen tensions with values of pO2 ranging from 20 to 80 mmHg, with a median value 
around 50 mm Hg, none of them less than 10mm Hg (6). However, the oxygen levels reported for 
tumors are very often lower than those of healthy tissues. In this context, oxygen tensions that may 
be considered normoxic in some tissues may represent hypoxic situations for others, and vice versa, 
as illustrated in Table 1.  
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Table 1. Median values of pO2 determined in different tissues and cancer types. 
Healthy Tissue Median pO2 (mmHg) Reference 
Breast 52 (206) 
Subcutis 51 (206) 
Skeletal muscle 37 (206) 
Cervix 42 (207) 
Pancreas 57 (210) 
Rectal mucosa 52 (210) 
Kidney 31 (210) 
Skeletal muscle 25 -30 (210) 
Liver  30 (210) 
Brain 24 - 27 (210) 
Neoplastic tissue Median pO2 (mmHg) Reference 
Breast cancer 3-15 (206) 
K1735 malignant melanoma 37.8 ± 5.1 (231) 
RENCA renal cell carcinoma 24.8 ± 17.9 (231) 
Lewis lung carcinoma 1.8 ± 1.1 (231) 
Cervix cancer 10 (207) 
Soft tissue sarcoma 20/7.5
a
 (28) 
Cervical carcinoma 4.5 (27) 
Squamous carcinoma metastatic to lymph nodes 12.6 (27) 
Head and neck cancer 4.8/4.3
b
  - 9 (29) - (145) 
Uterine cervix 12.5 - 9 (207) - (210) 
Prostate Cancer  2 - 21 (210) 
Brain tumors 13 (210) 
a
 Median values for non-recurrent/recurrent tumors respectively. 
b 
Median values for primary/metastatic (cervical nodes) tumors respectively. 
1.1.2. Causes and consequences of tumor hypoxia 
 
Tissue hypoxia arises from an imbalance between the oxygen demands of the tissue and the capacity 
for oxygen delivery of the neighboring microvasculature. Its main causes and consequences are 
summarized in Figure 2.  
Oxygen consumption in tumors may be increased up to five-fold as a result of the augmented 
metabolic demand of rapidly growing cancerous tissues (134). On the other hand, oxygen availability 
to the tumor will depend on the adequate performance of its microvascular bed, and thus on the 
efficiency of neovascularization (77,134,144). These processes are tightly balanced in normal tissues, 
but their regulation is often lost in cancer, resulting in abnormal microvasculature performance, 
reduced perfusion and impaired oxygen or nutrient delivery to the tumor (57,138). Vascular 
deficiencies in tumors can be broadly divided into structural or functional. Structural deficiencies 
include caliber variations with dilated and narrowed single branches of tumor vessels, chaotic 
vascular networks and disturbed precapillary architecture. Functional limitations consist basically of: 
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immature vessels, increased transcapillary and vascular permeability, interstitial hypertension, 
increased flow resistance and nonperfusing vessels (57,133). However, the aberrant neovasculature 
may not be the only cause of reduced oxygen availability in the tumor. Additional causes may include 
low environmental pO2, as in pulmonary disease, or the inability of cells to use oxygen properly 
because of a toxic challenge, as in cyanide poisoning (80). Tumor- or therapy-related anemia may 
also dicrease the global capacity of blood to transport oxygen, aggravating this situation (205).The 
first recognized consequence of hypoxia is the shift from aerobic to anaerobic metabolism (42), a 
circumstance known as the Warburg effect (60). Reduced oxygen availability is currently known, 
however, to induce important genomic and proteomic changes in cells. Numerous links have been 
reported between tumor hypoxia and an increased ability to metastasize (112,163), induce 
angiogenesis (77,112), apoptosis (57,64,71), cell immortalization (186), expression of growth factors 
for cell proliferation (71,112,187), cellular dedifferentiation (74) and genetic instability (80). All these 
changes are largely thought to be a result of hypoxia-driven alterations in the expression of a battery 
of hypoxia-sensitive genes (35,71,187). Remarkably, very important overlaps exist between hypoxia-
induced genes and activated cancer pathways. Some oncogenes, tumor suppressor genes, stress 
proteins and cytokines induced by hypoxia are constitutive of well-known cancer pathways, and 
increasing evidence supports the close dialog between hypoxia and some oncogenic signaling 
pathways (126).  
Figure 2. Main causes (top) and consequences (bottom) of tumor hypoxia.  
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1.1.3. Molecular mechanisms of hypoxia 
 
Figure 3 illustrates our current understanding of the molecular events underlying hypoxic responses. 
Hypoxia-responsive genes are activated by means of hypoxia-inducible factor-1 (HIF-1). HIF-1 is an 
oxygen-sensitive transcription factor that eventually binds to hypoxia-response elements (HREs), 
activating a battery of genes to recover oxygen homeostasis. HIF-1 is a heterodimer that consists of 
the constitutively expressed aryl hydrocarbon receptor nuclear translocator (ARNT or HIF-1E) and the 
HIF-1D subunit sensitive to oxygen concentration (126,196). The translation of high oxygen levels to 
decrease HIF-1 activity is driven by the prolyl hydroxylase-domain protein (PHD), hydroxylating the 
HIF-1D subunit and allowing the interaction with the Von Hippel W Lindau tumor-suppressor protein 
(pVHL). This complex is recognized by the E3 ubiquitin-protein ligase, which ubiquitinates HIF-1D and 
labels it for proteasomal degradation (187). Oxygen is the limiting factor for these reactions under 
normoxic conditions. Under hypoxic conditions, HIF-1D is not hydroxylated and can upregulate its 
target genes. There is an additional regulation sentinel, the factor inhibiting HIF-1 (FIH). FIH is an 
oxygen- and iron-dependent hydroxylase operating over HIF, but in a different residue than PHD, 
inhibiting the interaction of HIF with CBP/ p300, an essential coactivator of HIF (188). As these two 
hydroxylases have different oxygen sensitivities, it is possible to fine tune the resulting HIF-1 activity 
to different oxygen levels (179). In addition to oxygen, HIF-1 can also be activated in response to 
other stimuli-like growth factors, cytokines and some signaling pathways, such as 
phosphatidylinositol 3-kinases (PI-3k), protein kinase B (Akt)and the Ras-MEK-ERK pathway 
(168,188). HIF-1 is not the only transcription factor activated by oxygen limitations. Additional factors 
include cyclic AMP-response element- binding protein (CREB), metal-transcription factor-1 and 
nuclear factor-kB (NF-kB) (71,80). There are other cellular responses to low oxygen levels, including 
the unfolded protein response (52) and inhibition of the initial step of mRNA translation (221). 
Figure 3. Regulation of hypoxia-inducible factor (HIF) activity by molecular oxygen.  
Oxygen (O2) is the limiting factor for HIF-D hydroxylation. Under normoxic conditions, the HIF-D subunit is 
hydroxylated by prolyl hydroxylase-domain protein 1 W3 (PHD 1 W3). The hydroxylated HIF-D is recognized by the 
Von Hippel WLindau (VHL) complex and labeled with ubiquitin for proteasomal degradation through the E3 
ubiquitin-protein ligase. Under hypoxic conditions, HIF-D is not hydroxylated, forming a complex with aryl 
hydrocarbon receptor nuclear translocator (ARNT; HIF-E) and CBP/p300 that upregulates the pleiotropic 
expression of genes containing a hypoxia-responsive element (HRE). FIH, factor inhibiting HIF-1. 
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Many indications suggest that HIF-1 is the molecule responsible for hypoxia-driven tumor 
aggressiveness and resistance to therapy. A number of experimental studies and clinical reports have 
provided a direct correlation between HIF-1D overexpression and cancer progression, invasiveness, 
resistance to therapy, and poor patient outcome (35,71,112). Nevertheless, the role of HIF-1D in 
tumor growth and invasiveness may be complemented by other factors, such as the 
microenvironment, which may even play a determinant role in these processes (21). Molecular 
imaging approaches are being designed to visualize directly and noninvasively the molecular 
determinants of hypoxia or related signaling events and their behavior in targeted tumor therapies 
(193). Currently, the development of new molecular imaging methods to visualize directly and 
noninvasively hypoxia and hypoxia related pathways is one of the most active areas of research in 
the molecular imaging community (193).  
1.1.4. Metabolic and cellular heterogeneity of hypoxia 
 
Limitations in oxygen levels influence differently various cellular processes and have different 
impacts in normal and neoplastic cells (Table 2). Although normal cells react to hypoxia through cell 
cycle arrest, apoptotic or necrotic mechanisms, tumor cells adapt more easily to the hostile 
environment, developing sophisticated escape mechanisms and becoming resistant to therapies. The 
differential effects of hypoxia on the vital cellular events of normal and neoplastic cells result in 
different survival rates, even in spatially very close cellular populations, leading to highly 
heterogeneous tissue and tumor oxygenation environments.  
Table 2. Differential effects induced by hypoxia in normal or tumoral cells. 
 
Normal cells 
a
 Tumor cells 
b
 
Apoptosis by p53-dependente and p53±
independent pathways
 
Adaptation to hostile environment (deprivation 
of nutrients and oxygen)  
Necrotic cell death occurs below a critical 
energy levels 
Develop escape responses to the hostile 
environment (tumor cell detachment and 
subsequent adhesion, migration, angiogenesis, 
tissue remodeling)  
Cell cycle arrest, quiescence and differentiation Increased resistance for cell cycle arrest, 
differentiation and apoptosis  
Impaired cell growth  Increased resistance to different therapies 
a 
These effects are also observed in some neoplastic cells. 
b 
These changes could explain hypoxia associated 
tumor aggressiveness, metastatic potential and resistance to various therapies (166). 
 
Figure 4 summarizes the effects of different degrees of hypoxia on some crucial metabolic pathways 
involved in cellular survival. Notably, the boundary pO2 values limiting the efficacy of the various 
cellular processes and therapies are different. Although vital events, such as the oxygen consumption 
by mitochondrial respiration and the loss of apoptotic potential, require extremely severe reductions 
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with pO2 below 0.5 mmHg, different therapies become ineffective below 15 mmHg. It should be 
noted, however, that these boundary values derive from different experimental designs for each 
process, and that other factors (pH, nutrient levels, etc.) may also modulate oxygen sensitivity, 
making the resulting panorama even more complex 
Figure 4. Sensitivity profiles to oxygen depletion (pO2) in different therapies ( ), cellular functions ( ) and 
molecular mechanisms ( ). 
Darker squares indicate pO2 intervals eliciting an activity change. Above these levels, therapies are effective 
and cellular and molecular processes appear to proceed normally. Below these levels, therapies are not 
effective and the indicated cellular and molecular processes are discontinued. 
 
To summarize, hypoxia is an important prognostic factor having different effects in normal and 
neoplastic cells, as well as on different cellular and metabolic processes. Beyond any molecular or 
physiological consideration, hypoxia is believed to induce a selective pressure in neoplastic cells, 
forcing their adaptation to a hostile environment characterized by oxygen and nutrient deprivation. 
This environmental pressure has been proposed as the driving force for the natural selection of 
resistant cells depicting a more malignant and metastatic phenotype (64,79).  
1.2. Experimental approaches for the measurement of hypoxia 
 
The implications of appropriate pO2 measurements in the design of the most adequate therapy or 
combination of therapies, as well as for the understanding of basic biological events in tumors, are 
well illustrated in Table 2 and Figure 4. These important processes determine, in part, the 
requirements of the optimal measuring methodology. As heterogeneity is an important property of 
the hypoxic phenotype, its detection and resolution in space and time domains becomes, necessarily, 
a significant issue in the design of the most adequate imaging technology.   
Table 3 summarizes the most relevant methodologies used to measure hypoxia, together with their 
characteristic features. The ideal properties of a hypoxia measurement technique include 
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noninvasiveness, adequate spatial and temporal resolution, quantitative measurement, no oxygen 
consumption, adequate range of pO2 values measured and, if an exogenous agent is required, 
exhaustive knowledge of its toxicology and pharmacodynamic properties (121). Unfortunately, there 
is not currently an in vivo method that fulfills satisfactorily all these requirements.  
&Žƌ ŵĂŶǇ ǇĞĂƌƐ ? ŽǆǇŐĞŶ ĞůĞĐƚƌŽĚĞƐ ǁĞƌĞ ĐŽŶƐŝĚĞƌĞĚ ƚŽ ďĞ ƚŚĞ  ‘ŐŽůĚ ƐƚĂŶĚĂƌĚ ?(133) in hypoxia 
measurements, supporting the development of several clinical studies (59,78,167). Recent reports, 
however, suggest that no universal gold standard exists at present (151,196). Nowadays, different 
methods to measure tissue oxygen levels in situ have been tested, such as O2 electrodes 
(67,145,211), PET (56,158,212), single photon emission computed tomography (SPECT) (56,158), 
immunohistochemistry (114), near-infrared spectroscopy (NIR) (113,212) and phosphorescence 
(212). Among them, Magnetic Resonance (MR) presents several characteristics that make this 
technique particularly suitable for this purpose. 
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Table 3. Main characteristics of various techniques used to assess in vivo hypoxia. 
 
Technique Mechanism 
Temporal 
resolution 
Spatial 
resolution 
Advantages Disadvantages 
O2 electrodes 
Polarographic current 
generated by the reduction 
of molecular oxygen 
s ȝP-mm Direct measurement of O2 FRQFHQWUDWLRQ&RQVLGHUHGDV³JROG
VWDQGDUG´([WHQVLYHOLWHUDWXUH 
Invasiveness. Oxygen consuming. 
No imaging possible. Necrotic areas 
a 
 
Fiber optic  
Oxy-Lite 
Fluorescence quenching by 
dissolved O2 
s Pm-mm Direct measurements of pO2. No oxygen 
consumption. Simultaneous temperature 
measurement  
Invasiveness. Short half life of probe 
Point measurement. No imaging possible 
Immunohistochemistry  
(2-Nitroimidazole)
 
Fluorescence of drugs 
selectively trapped on 
hypoxic cells 
h ȝm High spatial resolution 
Highly standardized  
Only viable hypoxic cells give signal 
Non quantitative measurements 
Averaged hypoxic areas over sampled time 
Biopsy needed 
19
F MRS/MRI 
Perfluorocarbons 
3HUIOXRURFDUERQV¶
relaxation properties 
m ȝP-mm Imaging possible 
Non consuming oxygen 
Dynamic studies 
Intratumoral injection 
Necrotic areas 
a
 
Non clinical implementation of 
19
F-MR 
1
H MRS 
Endogenous 
1
H metabolites 
levels, lactate 
m mm-cm Comprehensive 
Metabolomic information 
Low spatial and temporal resolution 
Indirect, qualitative, pO2 detection through 
lactate resonance 
31
P MRS 
Endogenous 
phosphorilated metabolite 
levels, ATP, PCr, Pi 
m mm-cm Comprehensive 
Bioenergetic information 
Very low spatial and temporal resolution 
Indirect, qualitative, pO2 detection through, 
Pi, PCr or ATP changes 
MRI BOLD 
Magnetic susceptibility 
changes created by 
oxygenation/deosygenation
of Hb 
ms ± s ȂP Imaging at high spatial and temporal 
resolution. Non invasive. No Oxygen 
consumption 
Many factors (blood flow, anemia, etc.) can 
affect the measurement. 
MRI DCE 
Dynamic transit of 
paramagnetic contrast 
agent 
ms-s mm Non invasive. Multiple parameters 
determined:, blood volume, blood flow, 
mean transit time, capillary permeability 
Limited spatial resolution. Strict instrumental 
requirements (EPI). Model dependent 
Indirect measurement pO2 
MRI-DWI 
Apparent translational 
diffusion of tissue water 
m 
 
Pm Non invasive. High spatial resolution. 
Very sensitive to tissue anisotropic 
microstructure, cellularity and edema 
Indirect measurement pO2 
High image processing demands (DTI) 
Multiexponential behaviour ADC 
EPR 
Variation in EPR resonance 
width 
s ± h ȝP-mm Non invasive. No Oxygen Consumption.  
Dynamic studies 
Small range of pO2 values covered 
Difficult clinical implementation 
PET 
PET labeled compounds 
selectively trapped in 
hypoxic cells 
m ± h mm-cm Non invasive. High sensitivity. Only 
viable hypoxic cells give signal 
Radioactive compounds. Short half live 
Small range of pO2 values covered 
Low spatial resolution 
a 
Necrotic areas : no discriminating between living cells and necrotic tissue 
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1.2.1. Measurements of hypoxia by Magnetic Resonance Imaging 
1.2.1.1. Perfluorocarbons (PFCs) 
 
PFCs are organic molecules in which all hydrogen atoms have been replaced by fluorine atoms, hence 
providing a strong 19F MR signal (129). PFC compounds were initially developed as artificial blood 
substitutes and oxygen carriers. However, PFCs display a series of properties that make them very 
appropriate to be used as MR contrast agents. In particular, they are biologically inert, exhibit minimal 
toxicity and are commercially available. There are different types of PFC: linear and cyclic. Figure 5a depicts 
the structures of some of the most commonly used PFCs in oxymetry.  
Figure 5. Perfluorocarbons as oximetry probes.  
a) Different PFCs used in oximetry: perfluoro-15-crown-5-ether;  hexafluorobenzene (HFB) and F-44E. b) Illustrative 
MRI oximetry of H460 human tumor xenograft (0.57 cm
3
) implanted in a nude rat. Fluorocarbon relaxometry using 
echo planar imaging for dynamic oxygen mapping (FREDOM) was used to acquire pO2 maps with an in-plane 
resolution of 1.25mm (5mm thick) in 6.5 min each while the rat breathed air (left) or oxygen (right).  
 
To our knowledge, Parhami and Fung (159) were the first to show that a linear relationship exists between 
the 19F MR spin-lattice relaxation rate (R1=1/T1) of PFC and oxygen tension, a circumstance most probably 
caused by the inherent paramagnetism of the oxygen molecule. Since then, many studies have exploited 
this phenomenon to measure pO2 by 
19F MR. The same paramagnetic effect has been reported in other 
molecules, including water (98,110,229). However, in the latter case, many other factors, including metal 
ions, pH and temperature, also induce changes in water relaxivity in vivo, making the results observed more 
difficult to interpret exclusively in terms of pO2 variations. In contrast, R1 of PFCs is not usually affected by 
hydrophilic charged species (143) as these hydrophobic molecules do not mix with the surrounding 
aqueous phases, forming droplets or emulsions that preclude ions from entering the hydrophobic core 
(197). However, oxygen solubility is greater in PFCs than in water, and so these compounds may even be 
considered as molecular amplifiers of oxygen tension. Nevertheless, despite the differences in oxygen 
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solubility between PFCs and the surrounding medium, pO2 between both phases will become the same 
after a short (usually seconds) equilibration interval (229). As a consequence, PFCs exhibit high sensitivity to 
oxygen changes and their detection. Furthermore, at a given magnetic field (B0) and temperature (T), there 
is a linear relationship between R1 and pO2 of PFCs [R1=a + b pO2, where a is the anoxic relaxation rate and 
b is the relaxation rate caused by the paramagnetic contribution of oxygen (99)]. With this equation, in vivo 
measurements of R1 can be transformed easily into pO2 maps using in vitro calibration curves (123). This 
method has been standardized by comparing the values obtained with PFCs with those obtained with 
electrodes (90,122), although discrepancies have also been found (174).  
PFCs (pure or in emulsions) have been investigated for the measurement of tissue oxygenation in vivo 
(129,229). In particular, HFB (Figure 5a) has been used to investigate oxygenation and response to 
respiratory challenge of different tumor types using a number of different strategies. HFB presents several 
properties that make it especially suitable for this purpose (high R1 sensitivity to pO2, small temperature 
dependence and low toxicity (120)). Zhao et al. (87) ĚĞǀĞůŽƉĞĚ Ă ƉƌŽĐĞĚƵƌĞ ĐĂůůĞĚ  ‘ĨůƵŽƌŽĐĂƌďŽŶ
ƌĞůĂǆŽŵĞƚƌǇ ƵƐŝŶŐ ĞĐŚŽ ƉůĂŶĂƌ ŝŵĂŐŝŶŐ ĨŽƌ ĚǇŶĂŵŝĐ ŽǆǇŐĞŶ ŵĂƉƉŝŶŐ ?  ?&ZKD ) ? ǁŚŝĐŚ ĞŶĂďůĞĚ ƚŚĞ
imaging of the oxygen tension in vivo More recently, Jordan et al. (94) used a snapshot inversion recovery 
pulse sequence, allowing very fast HFB mapping (1.5 min) without sacrificing precision or spatial resolution. 
Representative pO2 maps of H460 human non small cell lung carcinoma, implanted subcutaneously into 
nude rats, are shown in Figure 5b for animals breathing air (left) or oxygen (right) (156). 
1.2.1.2. Proton probes analogous to PFC  
 
The utilization of 19F MR oximetry in clinical settings has been delayed, mainly because clinical scanners 
usually lack 19F MR capability. Thus, the development of 1H MR-based pO2 probes could represent a critical 
advance for the routine measurement of tissue oxygenation and the optimization of therapeutic regimes 
under current clinical conditions. 
Recently, Kodibagkar et al. (88) have proposed a proton analog to PFCs, hexamethyldisiloxane (HMDSO, 
Figure 6), as a novel 1H MR oximetry probe. The HMDSO resonance is located close to 0 ppm, 
approximately 1 ppm below the methylene fat resonance but sufficiently far away to avoid interferences. 
HMDSO shares some important properties with PFCs: it is highly hydrophobic and nontoxic, shows high 
oxygen solubility, is biochemically inert in vivo, and is readily available and relatively inexpensive (91). 
HMDSO has long half-life (35 h) which may facilitate the study of chronic changes, reducing clearance from 
the tumor and improving the signal to noise during the measurement. Similarly, the short T1 value may 
improve the temporal resolution, allowing faster pulsing rates and favoring the accumulation of R1 data in 
hypoxic zones. 
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Figure 6. 
1
H analogs to perfluorocarbons used as oximetry probes.  
(a) Chemical structure of hexamethyldisiloxane (HMDSO). (b) Proton imaging of siloxanes to map tissue oxygenation 
levels (PISTOL), was used to acquire pO2 maps with an in-plane resolution of 1.25mm (1mm thick) in 3.5 min while the 
rat breathed air (left) or oxygen (right). Maps are presented superimposed to a T1-weighted image of the tumor.  
 
HMDSO also presents some disadvantages when compared with PFCs, mainly because of the strong 
background signal in 1H MR, a circumstance not occurring in 19F MR. Kodibagkar et al. (100) implemented, 
for this purpose, a method named Proton Imaging of Siloxanes to map Tissue Oxygenation Levels (PISTOL). 
This new approach has been validated by comparison with the well-established HFB-FREDOM 
approximation described above. Indeed, baseline and modifications in pO2 values in tumors  and thigh 
muscle are similar for both methods (100), as well as for those previously reported in the literature (88). 
One of the major advantages of the HMDSO method is that translation to the clinic may be possible in the 
near future allowing the combination of oximetry information with that derived from other routinely used 
1H MR-based methods, such as dynamic contrast enhancement (DCE), translational diffusion 
measurements and magnetic resonance spectroscopy (MRS). 
1.2.1.3. Blood Oxygen Level Dependent (BOLD) contrast  
 
BOLD contrast can be used as a functional MRI technique that affords a measurement of blood oxygenation 
by using sequences sensitive to changes in T2*. The method is based on the fact that deoxyhemoglobin is 
paramagnetic, whereas oxyhemoglobin is diamagnetic. Therefore, changes in 
deoxyhemoglobin/oxyhemoglobin ratio related to variations in oxygen concentration in blood, will 
influence the relaxation of water protons (particularly T2*), enabling blood oxygenation levels to be 
measured by MRI. Originally, the BOLD approach was developed to investigate cerebral activity, being 
extended more recently to the assessment of tumor oxygenation in response to hyperoxic gas challenge 
(141,158). Early BOLD MRI investigation in tumors were performed by Karczmar et al. (93) using 100% O2 in 
a R3230AC mammary adenocarcinoma model, followed by the work of Robinson et al. (173) using carbogen 
in a GH3 prolactinoma model. They both found changes in BOLD signal intensities as large as 50% and 
100%, respectively. Several studies have shown that changes in signal intensities of T2* weighted (T2*W) 
images and T2* values reflect changes in tumor oxygenation, and they have potential value as prognostic 
a  b 
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indicators (176). However, a quantitative relationship between the BOLD effect and pO2 has not been found 
(15), probably because of the complex relationship between these two parameters (89). Indeed, in addition 
to oxygenation, the BOLD effect is influenced by other factors different from pO2, including blood flow, 
hemoglobin levels, vasculature, etc. These circumstances prompted the use of the ĂĐƌŽŶǇŵ ‘&>KK ? ?ĨůŽǁ
and oxygenation dependent) to refer to the BOLD experiment as applied to the study of oxygenation in 
tumors (83).  
1.2.1.4. Tissue oxygen level dependent (TOLD) contrast 
 
Recently, tissue oxygenation has been proposed to be measured using the paramagnetic nature of oxygen 
and the shortening of the tissue water T1 value during hyperoxic gas breathing (125). Indeed, molecular 
oxygen has two unpaired electrons and may act as a paramagnetic contrast agent, shortening the water T1 
value, thus reflecting tissue oxygenation rather than blood oxygenation.  
A number of clinical studies have been performed to assess the variations in R1 and R2* in response to 
carbogen or pure oxygen breathing in different organs (spleen, liver, renal cortex) and normal tissues 
(muscle, subcutaneous fat) (146,147). Significant increases in R1 were found in all cases, whereas R2* only 
showed significant changes with carbogen, but not under pure oxygen breathing. The magnitude of these 
responses was found to be organ and tissue dependent. Changes in tumor ?Ɛ R1 values in response to 
hyperoxic gas breathing were clinically assayed in various types of cancer (ovarian adenocarcinoma, colon 
carcinoma, cervix squamous carcinoma) (148). The results were compared with those obtained with DCE 
MRI, finding regions of positive correlation (high or low perfusion corresponding to good or bad 
oxygenation) and also zones of mismatch (areas of moderate perfusion and low oxygenation). The 
quantitative relationship of these variations with changes in pO2 merits, however, further investigation. 
1.2.2. Measurement of hypoxia by MRS 
 
Both 1H and 31P MRS in vivo spectra have provided only an indirect assessment of the tissue oxygen tension 
with limited resolution (millimeters in animal scanners and centimeters in currently available clinical human 
scanners). Oxygen limitations in tumors typically lead to increases in the lactate and total choline 
resonances detected by 1H MRS (107) or increases in the phosphomonoester peak and inorganic 
phosphate/phosphocreatine (Pi/PCr) ratios observed by 31P MRS (30,111,142). Thus, it would become 
considerably useful to introduce an external agent, directly sensitive to hypoxia, detectable by MRS. 
1.2.2.1. Nitroimidazoles  
 
Nitroimidazolyl derivatives have been used extensively in South America since the 1970s as therapeutic 
agents against Trypanosome Cruzi ? ƚŚĞ ƉƌŽƚŽǌŽĂŶ ĐĂƵƐŝŶŐ ŚĂŐĂƐ ? ĚŝƐĞĂƐĞ ? ^ŝŶĐĞ ƚŚĞŶ ? ƚŚĞƐĞĐŽŵƉŽƵnds 
have found several applications, including antibacterial and antiprotozoal drugs (nifurtimox, metronidazole) 
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(44), cytotoxic molecules against hypoxic cells (95,218), radiosensitizers and chemopotentiation drugs in 
adjuvant therapies (44,218) and, more recently, hypoxia markers using 19F MR (95), PET (56,86,102,103), 
SPECT (86) and immunohistochemistry (20).  
To our knowledge, Varghese et al.  (200) were first to report that 14C-labeled misonidazole (14C-MISO) was 
selectively trapped in hypoxic cells. Subsequent studies associated this with the enzymatic reduction of the 
nitro group (218). The most widely accepted metabolism of nitroimidazole derivatives under aerobic and 
anaerobic conditions is briefly summarized in Scheme 1. In both cases, the reaction begins with 
transformation of the parental compound into an anion radical through the addition of one electron by the 
nitro group. Under aerobic conditions, the anion reacts with molecular oxygen, producing a superoxide 
anion and the original compound, producing a futile cycle. The superoxide anion is transformed by 
superoxide dismutase (SOD) to hydrogen peroxide, leading to a series of reactive oxygen species 
responsible for nitroimidazole toxicity in normal, i.e. aerobic, tissue (26). Otherwise, under hypoxic 
conditions, the anion radical can be further reduced by nitroreductases into a nitroso derivative. Additional 
reductions will transform the nitroso metabolite subsequently into hydroxylamine and finally in amine 
derivatives. These bind easily to cellular components, forming covalent bonds with sulfhydryl groups (such 
as those of reduced glutathione), thus becoming selectively trapped in hypoxic cells since binding to 
normoxic cells does not occur to the same extent. The chemical reduction of hydroxylamine derivatives and 
the subsequent chemical transformations have been extensively investigated in vitro, but few clues exist 
into the mechanisms operating in vivo (23,203). 
 
Scheme 1. Bioreductive transformations of nitroimidazole derivatives under anaerobic or aerobic 
conditions in vivo. 
 
Notably, an important consequence of its in vivo metabolism is that nitroimidazole-based methods only 
account for viable hypoxic cells, i.e. those able to reduce the nitro moiety, in contrast with other techniques 
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that measure directly the pO2. It is important to note that direct relationships between oxygen 
concentration and nitroimidazole reduction have been reported previously both in vitro (3,91) and in vivo 
(116). Nitroimidazole markers of hypoxia are normally used in combination with different detection 
techniques, such as MRS, MRI, PET (F-MISO and copper diacetyl-bis-N(4)-methylthiosemicarbazone (Cu-
ATSM)) (114,158), SPECT (iodinated azomycin arabinoside) (41) and immunohistochemistry (Pimonidazole 
and EF5) (51,97), thus adding the advantages and disadvantages of the detection method employed to 
those of the corresponding biomarker molecule.  
The interpretation of the results from hypoxia measurements using nitroimidazole-based drugs remains 
complex as it involves three simultaneous processes with their characteristic rate constants (128): (i) 
marker bioreduction and binding in hypoxic cells; (ii) excretion of the marker (and eventually its products); 
and (iii) if radioisotopes are used, their lifetimes. Accordingly, the amount of nitroimidazole derivative 
observed depends on how well it has reached and left the target tissue, as well as on the O2 concentration 
in the tissue, which determines, together with the redox properties of the compound, the amount of probe 
that remains trapped within the cellular structures. The first aspect depends on the blood flow, 
microvascular perfusion and marker lipophilicity, while the second one depends on the intrinsic redox 
properties of the nitroimidazole and the local oxygen tension. If the nitroimidazole derivative is labeled 
with short-lived radioisotopes, the signal intensity will also decrease with time because of radioactive 
decay. The balance of these different processes determines the optimal time point to be used in the 
measurement.  
A significant limitation is that nitroimidazole-based markers often target highly hypoxic cells, such as those 
with pO2 below 1 mmHg. Cells with higher oxygen concentrations, but still hypoxic, may not be detected, 
and some studies have shown that these cells with intermediate hypoxia levels are also important in tumor 
development and treatment failure (220). 
Attempts have been made to design rationally an optimized nitroimidazole molecule fulfilling all desired 
properties focusing on modifying lipophilicity, reduction potential and reactivity. To this end, the structure 
for most nitroimidazole-based hypoxia markers may be divided into two parts: the nitro moiety and the 
lateral chain. The former is linked to an aromatic ring (often imidazole) and is responsible for electron 
affinity, i.e. bioreduction, as defined by the reduction potential. The lateral chain is responsible for 
biodistribution, tissue penetration, elimination rate, etc. (185), ĐĂƌƌǇŝŶŐ ?ŝŶŵŽƐƚĐĂƐĞƐ ?ƚŚĞ ‘ƌĞƉŽƌƚĞƌĂƚŽŵ ?
(19F, 18F, 125/123I, 99mTc). Thus, the general properties of these molecules may be fine tuned for specific 
purposes by modifying appropriately either the imidazole ring or the lateral chain. The improvements to be 
achieved may include a more adequate partition coefficient, adequate solubility in aqueous medium, 
stability, more feasible synthesis, improved lipophilicity, etc. The most common nitroimidazole derivatives 
used as hypoxia markers are shown in Figure 7.  
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Several studies have been performed to compare the measurements obtained with nitroimidazole-based 
markers and other techniques with different results. Some reported a direct relationship between pO2 
measured by EPR and nitroimidazole retention (116). On the other hand, others found no correlation 
comparing results obtained with nitroimidazole derivative markers and Eppendorf electrodes or 19F MR 
methods (5,51,174). A possible explanation is that all of these techniques do not discriminate between 
necrotic or living tissues, whereas nitromidazoles bind exclusively to living cells. Another source of 
discrepancy is related to the different measurement times, as indicated in Table 3. Whereas polarographic 
electrodes or PFC-based measurements provide pO2 measurements limited to a single time point, 
nitroimidazole-based markers measure hypoxia through adducts accumulated in the hypoxic cell or tissue 
during the incubation time, thus hindering an appropriate direct comparison.  
 
Figure 7. Nitroimidazole derivatives currently used as molecular probes for hypoxia.  
Misonidazole (MISO) derivatives with 
18
F are used as positron emission tomography (PET) probes. Pimonidazole is 
used as an histochemical probe. EF5, SR-4554 and TF-MISO are 
19
F MR indicators. NISUCA is a novel 
1
H MRS probe 
developed and implemented in this thesis (155). 
 
A variety of approaches have been implemented using nitroimidazole based drugs as 19F MR oximetry 
probes. Early work carried out by Raleigh et al. (170) using CCI-103F showed the ex vivo detectability of 
bound derivatives in tumor and liver by 19F MR. Soon after, the in vivo implementation of CCI-103F and Ro 
07-0741 were reported (127) and the ex vivo concentration of bounded markers in subcutaneous tumors 
(R3327 H NS R3327 AT prostatic adenocarcinomas and walker 256 carcinoma) or in liver were quantified 
using 19F MR (171). 
More recently, two fluorinated nitroimidazole derivatives, SR-4554 and TF-MISO (Figure 7), have been used 
to measure hypoxia in vivo. The former has been studied extensively both in vitro (3) and in vivo with 
different tumor types (4), showing low toxicity, high metabolic stability, favorable pharmacokinetics and 
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high sensitivity for detection by MRS (2). Authors used a new parameter, named the 19F retention index (19F 
RI), indicative of tumor hypoxic fraction. This variable was defined as the ratio of the SR-4554 signal 
intensity, measured by 19F MRS, 45 min and 6 h after injection of the marker (4). It is assumed that the 
signal at 45 min reflects the total parent compound, whereas the signal at 6 h detects the reduced, and 
therefore retained, compound. This index shows a good correlation with previously reported 
radiobiological hypoxic fractions of four murine tumors (EMT6, SCCVII, KHT and RIF-1) (4). A close 
relationship of 19F RI and polarographic electrode measurements in rats bearing P22 carcinosarcoma has 
been reported (183). On these grounds, SR-4554 entered recent Phase I clinical trials (184). The 
pharmacokinetic and toxicity profiles appear to be favorable for use as a hypoxia marker. More recently, a 
mean retention index of 13.6 in human neoplasms has been reported, compared to the retention index of 
4.1 found in plasma samples obtained simultaneously with the spectroscopic measurement, revealing the 
presence of hypoxia in those tumors (108). 
Procissi et al. (169) proposed 2-Nitro-D-[(2,2,2-trifluoroethoxy)methyl]-imidazole-1-ethanol (TF-MISO) as a 
plausible 19F MR nitroimidazole-based reporter. They observed that cellular drug uptake increased with 
concentration and the time of incubation in anoxic conditions (compared to normoxia). The TF-MISO 
resonance linewidth increased with time after injection in murine tumors and T1 in vivo became much 
shorter than in a phantom. These spectral changes were proposed to reveal the presence of the bound 
adduct produced during the hypoxic challenge in vivo. A positive correlation was found in vivo between the 
corresponding retention index and the tumor volume (qualitatively related to tumor hypoxia). Finally, 
multivoxel spectroscopy has been achieved in tumors in vivo, showing that TF-MISO is visible under these 
conditions. Based on spectroscopic measurements, pharmacokinetic parameters and a biexponential 
model, the authors calculated the hypoxic fraction of the tumor and compared the results with literature 
values, finding similar results in MCa tumors. Although this methodology is far from being clinically 
applicable, it represents an important advance, as it proves for the first time, that a nitroimidazole-based 
drug may be spatially resolved by multivoxel spectroscopy in vivo.  
1.2.3. Measurement of hypoxia by EPR 
 
Molecular oxygen is paramagnetic, making EPR a theoretically optimal technique for direct, sensitive and 
noninvasive tissue oximetry. Unfortunately, the direct detection of dissolved oxygen in fluids is not possible 
because of the large broadening of its spectral lines. Therefore, indirect methods had to be developed. 
These methods rely on the administration of a paramagnetic probe, the EPR properties of which are altered 
by the surrounding paramagnetic oxygen, most commonly through the modification of its electron 
relaxation processes. The most frequently implemented method uses oxygen-induced T2 shortening and 
concomitant broadening of the principal hyperfine line of the EPR spectra from the probe. Optimal 
paramagnetic probes useful for EPR oximetry should have few, narrow EPR lines, good stability in biological 
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media, no toxicity and a linear dependence of R2 on oxygen concentration. Indeed, a direct relationship 
between the linewidth and percentage oxygen concentration can be found in vitro, and this calibration 
curve is used for in vivo determinations (94). 
There are two classes of paramagnetic probe currently used for in vivo oximetry: water-soluble and 
insoluble. The former include mainly the nitroxides and triaryl methyl radicals. The latter comprise lithium 
phthalocyanine and lithium naphthalocyanine (57). Because most stable molecules have all their electrons 
paired, the EPR approach is less extended than MR methods. However, this limitation provides the EPR 
technique with large specificity. Particularly, insoluble paramagnetic materials, once implanted, provide 
noninvasively repeated and accurate measurements of pO2 at the same site. Currently, considerable efforts 
are being dedicated to develop clinical applications for EPR oximetry. However, some issues still need to be 
overcome in order to convert it into a routine modality for the assessment of tissue oxygenation. These 
include, among others, safety and patient comfort for clinical studies and gaining of a consensus on the 
quantitative value of the measurements (194), In addition, EPR imaging technology has been developed 
and used to map oxygenation in vivo (212). 
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The main objective of this thesis is to develop and implement new methodologies to assess tumor 
hypoxia in vivo using MR methods. Two main approaches were developed here for this purpose; 1) 
Use of exogenous contrast agents and 2) Use of endogenous tissue contrast. 
 
1. Use of exogenous contrast agents 
To develop and implement the use of classical and novel nitroimidazole derivatives as 1H MRS 
contrast agents responsive to hypoxia. 
a. To investigate the reduction mechanism of Nitroimidazole derivatives in cell-free systems 
and disclose the main determinants governing their bioreduction. 
b. To investigate the reduction rate of these 2-nitroimidazolil probes and the influence of the 
different effectors conditioning it in cultures of C6 glioblastoma cells. 
c. To investigate the possibility of implementing in vivo this approach using implanted C6 
glioblastoma tumors, the oxigenation status of which is manipulated by modifying the 
oxygen content of the gas breathed by the animals and to examine the possibility to obtain 
hypoxia maps using this technology. 
 
2. Use of endogenous tissue contrast 
To combine BOLD and TOLD measurements to assess the response of tumoral pO2 to carbogen 
breathing based on differences in signal intensity in T1- and T2*-weighted images.  
a. To test this method using two rat prostate tumor types, noted for differential growth rates, 
vascular development and oxygenation. 
b. To assess the origin of the observed changes in T1- and T2*- weighted images by analyzing 
changes in tumoral relaxation rates (R1 and R2*) in response to carbogen breathing.  
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3.1. Synthesis and characterization of Imidazole Derivatives 
3.1.1. Analytical determinations   
 
Melting points were obtained on a microscope hot stage and are uncorrected. Elemental analyses 
were performed with Perkin-Elmer 240 apparatus. Mass Spectroscopy was carried out in a GC/MS 
Schimadzu QP-5000 equipment at 70 eV. For HRMS data, VG AutoSpec instrument was used. IR 
spectra were performed on a Philips PU-9700 and a Bruker vector 22 spectrophotometers. MR 
acquisitions were recorded with a Bruker DRX-400 (9.4 T). 1H and 13C chemical shifts (G) in CDCl3 are 
given from internal TMS and in D2O from internal TSP.13C chemical shifts in D2O are given from 
external DMSO-d6 with an accuracy of ± 0.01 for 1H and ± 0.1 ppm for 13C. The residual water signal 
in 1H MR spectra in D2O solution was suppressed when necessary using a 1 s (low power, 0.5 W) 
presaturating pulse applied with the decoupler. 1H W1H coupling constants (J) are accurate to ±0.2 Hz 
for 1H MR spectra. Thin Layer Chromatography was performed on DC-Aulofolien/Kieselgel 60 F245 
(Merck) and column chromatography through silica gel Merck 60 (230 W400 mesh). D2O (99.9 % D) 
was purchased from Apollo Scientific (Stockport, Great Britain). The rest of the products and 
anhydrous solvents were obtained from Aldrich of the highest purity available. 
Cyclic voltammetry measurements were carried out using an ECO Chemie Autolab PGSTAT 12 
potentiostat using the software package GPES 4.7 (General Purpose Electrochemical System). A 
Metrohm 6.0805.010 conventional glassy carbon electrode (3 mm o.d.) as the working electrode, a 
BAS MF-2063 Ag/AgCl/3 M KCl as the reference electrode and auxiliary electrode consisting of a Pt 
wire, which were directly immersed in the solution. A 10-mL electrochemical cell from BAS (model 
VC-2) was also used. E1/2 values were taken as the average of the anodic and cathodic peak 
potentials. The scan rate used was 100 mV s W1. 
3.1.2. Synthesis of NISUCA 
 
The preparation of NISUCA and its precursors is illustrated in Scheme 2 (155). 
Dimethyl 2-Nitro-1H-imidazol-1-ylbut-2-enedioates 2 and 3. 
A solution of dimethyl acetylenedicarboxylate (1.1 eq.) and 2-nitroimidazole (1 eq.) in MeCN (40 mL) 
was stirred at 65 °C for 3 days. After cooling to room temperature, the mixture was filtered and the 
solvent was evaporated in vacuo. Purification of the residual oil by column chromatography (silica 
gel, CH2Cl2 WEtOH, 100:0 to 95:5) allowed the separation of the isomers 2 and 3. 
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Scheme 2. Synthesis of NISUCA by termal addition of 2-nitroimidazole to dimethyl 
acetylenedicarboxylate. 
 
Dimethyl (Z)-2-(2-Nitro-1H-imidazol-1-yl)but-2-enedioate (2) 
White solid; yield: 61 %; mp 106 W108 °C (EtOAc). IR (ATR): 1733, 1717 cm W1. 1H MRS (400 MHz, 
CDCl3): G = 7.27 (d, J = 1.2 Hz, 1 H), 7.16 (s, 1 H), 7.06 (d, J = 1.2 Hz, 1 H), 3.86 (s, 3 H), 3.70 (s, 3 H). 13C 
MRS (100 MHz, CDCl3): G = 162.1, 161.2, 135.8, 129.0, 126.1, 125.6, 53.9, 52.7. Anal. calculated for 
C9H9N3O6: C, 42.33; H, 3.52; N, 16.46; found: C, 41.97; H, 3.50; N, 16.31. 
Dimethyl (E)-2-(2-Nitro-1H-imidazol-1-yl)but-2-enedioate (3) 
Yellow oil; yield: 17 %. IR (ATR): 1732, 1537 cm W1. 1H MRS (400 MHz, CDCl3): G = 7.20 (d, J = 1.2 Hz, 1 
H), 7.09 (d, J = 1.2 Hz, 1 H), 6.52 (s, 1 H), 3.85 (s, 3 H), 3.74 (s, 3 H). 13C MRS (100 MHz, CDCl3): G = 
163.2, 160.2, 133.3, 129.3, 127.7, 126.1, 53.5, 52.9. HRMS (EI): m/z [M+  W 31 (OMe)]. HRMS 
calculated for C8H6N3O5: 224.0307; found: 224.0304. 
 
Isomerization of E-isomer 3 to Z-isomer 2 
A solution of compound 3 (1 eq.) and p-toluenesulfonic acid (0.33 eq.) in MeCN was heated at 80 °C 
for 48 h. After cooling the solvent was evaporated in vacuo and the reaction crude was purified by 
+6.1 
MeCH, ' 
+ 
PTSA/MeCH, ' 
BH
3
, THF 
H
2
O, r.t. 
1 
2 3 
4 5 
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column chromatography (silica gel, CH2Cl2 WEtOH, 100:0 to 80:20) to give the corresponding 
compound.  
 
Preparation of dimethyl 2-(2-Nitro-1H-imidazol-1-yl)succinate (4) NISUCA 
To a solution of 2 (1 eq.) in anhydrous THF at 0 °C was added dropwise 1 M BH3·THF (1.15 eq.). The 
mixture was stirred under N2 for 1 h and kept at 10 °C for 8 h. Subsequently, the crude mixture was 
hydrolyzed in acidic medium (10 % HCl) at 0 °C and extracted with EtOAc. The combined organic 
layers were dried (Na2SO4) and the solvent was evaporated in vacuo. The residual oil was purified by 
column chromatography (silica gel, CH2Cl2 WEtOH, 100:0 to 80:20). 
Yellow oil; yield: 80 %. IR (ATR): 1737 cm W1. 1H MRS (400 MHz, CDCl3): G = 7.27 (d, J = 1.2 Hz, 1 H), 7.16 
(d, J = 1.2 Hz, 1 H), 5.90 (dd, J = 8.8, 4.4 Hz, 1 H), 3.77 (s, 3 H), 3.69 (s, 3 H), 3.31 (m, 2 H). 13C MRS 
(100 MHz, CDCl3): G = 169.8, 167.1, 128.3, 126.1, 58.2, 53.4, 52.4, 36.4. HRMS (EI): m/z [M+  W 46]. 
HRMS calculated for C9H11N2O4: 211.0719; found: 211.0714. 
 
(±)-2-(2-Nitro-1H-imidazol-1-yl)succinic Acid (5)  
A solution of ester 4 (150 mg, 0.58 mmol) in distilled H2O was stirred at room temperature for 30 d. 
The solvent was concentrated in vacuo and the hygroscopic residue was dried under reduced 
pressure (16 mbar) to give 5 as a white solid. 
Yield: 53 mg (40 %). 1H MRS (400 MHz, D2O): G = 6.47 (d, J = 2.8 Hz, 1 H), 6.42 (d, J = 2.8 Hz, 1 H), 4.98 
(dd, J = 8.8, 5.4 Hz, 1 H), 3.04 (2 m, 2 H) 
 
3.1.3. Synthesis of NIMAC 
 
 The preparation of NIMAC is illustrated in Scheme 3: 
 
Scheme 3. Synthesis of NIMAC by addition of 2-nitroimidazole to methyl bromoacetate. 
 
Methyl 2-(2-nitro-1H-imidazol-1-yl)acetate (6) NIMAC 
2-Nitroimidazole 1 (1 eq.) was added to a mixture of methyl bromoacetate (1 eq.), potassium 
carbonate (1.5 eq.), and TBAI (0.02 eq.) in acetonitrile. The mixture was heated to 80 ºC and stirred 
vigorously at this temperature for 40 min. After cooling to room temperature, the inorganic salts 
were removed by vacuum filtration and washed with acetonitrile. The filtrate and washings were 
6 1 
TBAI 
CH
3
CN, 80ºC 
+ K2CO3 
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combined and the solvents were evaporated in vacuo to give a residue that was recrystallized from 
ethyl acetate to yield methyl 2-(2-nitro-1H-imidazol-1-yl)acetate 6 (161).  
Yield: 80%. Mp, 95-96 oC.  1H MRS (400 MHz, D2O): ɷA? ? ? ? ? ?Ɛ ? ?, ) ? ? ? ? ? ?Ɛ ? ?, ) ? ? ? ? ? ?Ɛ ? ?, ) ? ? ? ? ? ?Ɛ 
3H). 
 
3.2. Kinetics of the enzymatic reduction of nitromidazoles in vitro as 
detected by 1H MRS. 
 
3.2.1. Experimental Design 
 
We investigated by high resolution 1H MRS the kinetics of reduction of nitromidazole derivatives in 
vitro using cell free systems in the presence and absence of either NADPH:cytochrome P450 
reductase (P450ase, E.C. 1.6.2.4) or glutathione reductase (GR, E.C. 1.8.1.7). Basically we monitored 
the kinetics of reduction of NISUCA, NIMAC, Misonidazole and Pimonidazole under different oxygen 
tensions, reactant and product concentrations and the in the presence or absence of either or both 
of the enzymes involved. We performed three types of experiments. First, we investigated the 
stability of reactants and products and the potential contribution of non enzymatic transformations 
during the reaction time by performing a series of incubations with cocktails containing individual 
substrates or products or mixtures of them, in the presence and absence of P450ase (Table 4). 
Second, we performed time course studies following the progress of the reaction under different 
substrates and effectors concentrations. Finally, we determined the apparent Km (Km´) and apparent 
Vmax (Vmax´) values to be able to interpret easier the events occurring in vivo. The following general 
red-ox reaction was investigated:  
 
Table 4 summarizes the incubation conditions employed to assess the stability and relative 
contribution of the different reactants and products to the overall process, using Misonidazole as a 
representative molecule. We performed these experiments in the presence and absence of P450ase, 
to assess the potential contribution of enzyme catalyzed and uncatalyzed processes. In these 
measurements we monitored the corresponding resonance intensities (Table 5) during 24h. We used 
reaction mixtures containing phosphate buffer (75 mM, pH= 7.7, 37 oC, 10% D2O), nitroimidazole 
derivative (5 mM), NADPH or NADP+ (15 mM), GSH (10 mM) or GSSG (5 mM) and P450ase (0.2 U/ml) 
where appropriate.  
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Table 4. Stability of substrates and products involved in misonidazole reduction, in the presence 
and absence of P450ase.  
+ indicates presence of the corresponding reagent or product at the specified concentration 
- indicates the absence of the corresponding reactant or product. 
Table 5. 
1
H chemical shifts and coupling constants of relevant protons from reactants and products 
involved in nitroimidazole reduction relevant to the kinetic analysis. 
 
a Chemical Shift (ppm) 
Compound 
a Ha b Hb b 
NISUCA 7.64 (d, J= 1.2 Hz, 1 H) [res #N1] 7.29 (d, J= 1.2 Hz, 1 H) [res #N2] 
MISO analog 7.48 (d, J=0.9 Hz, 1 H) [res #M1] 7.22 (d, J=0.9 Hz, 1 H) [res #M2] 
Pimonidazole 7.50 (d, J=1.1 Hz, 1 H) [res #P1] 7.24 (d, J=1.1 Hz, 1 H) [res #P2] 
NIMAC 7.50 (d, J=1.2 Hz, 1 H) [res #NM1] 7.28 (d, J=1.2 Hz, 1 H) [res #NM2] 
GSH 
3.13-2.80 (m, 2 H)  [res #GSH1] 
Cysteine, C E 
3.78 (t, J=6.3 Hz, 1 H) [res #GSH2] 
Glutamic, C D 
GSSG 
3.47-2.73 (m, 4 H) [res #GSSG1] 
Cysteine, C E 
3.78 (t, J=6.3 Hz, 2 H) [res #GSSG2] 
Glutamate, C D 
NADPH b 
6.95 (s, 1 H) [res #NADPH1] 
Nicotinamadie, N2 
6.00  (dd, J= 8.2, 1.3 Hz, 1 H) [res 
#NADPH2] 
Nicotinamide, N6 
NADP+ b 
8.415 (s, 1 H) [res #NADP+1] 
Adenosine, A8 
6.06 (d, J=5.5 Hz, 1 H) [res #NADP+2] 
EŝĐŽƚŝŶĂŵŝĚĞ ?E ? ? 
 
a 
See Figure 8 for chemical structures and numbering   
b
 Resonance numbers in square brackets are those indicated in the spectra of Figures 10, 12, 14 and 16.  
 
Incubation
Condition 
NADPH 
15 mM 
NADP
+ 
15 mM 
GSH 
10 mM 
GSSG 
5 mM 
MISO 
5 mM 
P450ase 
0.2 U/mL 
Information  
obtained 
1a + - - - + + 
Stability of NADPH 
1b + - - - + - 
2a - + - - + + 
Stability of NADP 
2b - + - - + - 
3a - - + - + + 
Stability of GSH 
3b - - + - + - 
4a - - - + + + 
Stability of GSSG 
4b - - - + + - 
5a + - + - + + Stability of GSH in 
the presence of 
NADPH 
5b + - + - + - 
6a + - - + + + Stability of GSSG in 
the presence of 
NADPH 
6b + - - + + - 
7a - + + - + + Stability of GSH in 
the presence of 
NADP 
7b - + + - + - 
8a - + - + + + Stability of GSSG in 
the presence of 
NADPH 
8b - + - + + - 
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Figure 8. Chemical structures of reactants and products and the corresponding specific protons used to 
follow the kinetics of nitroimidazole reduction. 
Chemical shifts and homonuclear coupling constants are those of Table 5. 
 
We performed time course experiments to investigate the evolution of reactants and products using 
phosphate buffered (75 mM, pH= 7.7, 37 oC, 10 % D2O) reaction mixtures containing the different 
hypoxia markers (5 mM), NADPH (15 mM), reduced glutathione (10 mM), P450ase (0.2 U/ml) and 
glutathione reductase (0.4 U/ml) where indicated.  
The impact of the initial hypoxia marker concentration in the reduction rate was evaluated by using 
different initial concentrations of MISO and NIMAC, varying between 1 to 20 mM. Samples were 
composed of phosphate buffer (75 mM, pH= 7.7, 37 oC, 10 % D2O), NADPH (15 mM), GSH (10 mM) 
and P-450ase (0.2 U/ml) and were treated as previously described, both in normoxic and anoxic 
conditions. Reaction was followed during two hours after the enzyme addition. A similar cohort of 
experiments was performed to obtain insight into the role of GSH in the reduction rate. In this case, 
samples were prepared analogously to the aforementioned conditions with the hypoxia marker 
concentration maintained at 5 mM and the GSH concentration varied in a 0- 20 mM range.  
 
Misonidazole  
Analog (MISO) 
NIMAC Pimonidazole  
(PIMO) 
Reduced glutathione (GSH) 
Oxidized glutathione (GSH) NADPH NADP
+
NISUCA 
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 3.2.2. High Resolution 1H MRS 
 
All reaction cocktails were prepared in 5 mm MR tubes (WILMAD, NJ, US) using TSP (1 mM) as 
internal reference and the tubes placed in 11.7T (500.13 MHz) Bruker AVANCE wide-bore (9.9 cm 
bore) spectrometer for high resolution 1H MRS.  Acquisition conditions ǁĞƌĞ Pʋ ? ?ƉƵůƐĞ ? 32K data, 6 s 
total cycle time, 128 acquisitions. In the stability experiments, spectra were acquired immediately 
after sample preparation and 24 h after, comparing both. In the time course studies under normoxic 
conditions, tubes were left open to equilibrate with the ambient environment during the complete 
MR acquisition. Anoxic conditions were induced by sealing the MR tube with a rubber septum and 
bubbling pure nitrogen for 30 minutes. The enzymatic reaction was triggered then where appropriate 
by the addition of NADPH:cytochrome P-450 reductase (0.2 U/ml), the tube was quickly placed in the 
magnet and spectra were acquired  during the next twelve hours. 
Figure 8 shows the structures of the main reactants and products involved in the reduction of 
nitroimidazole derivatives and allows to identify specifically the chemical shifts (G) and multiplicities 
of the different resonances used for the analysis (see Table 5). 
Resonance assignments were made based on the chemical shifts and multiplicities of the different 
protons summarized in Table 5 and Figure 8. Concentrations were calculated based on the known 
TSP signal integral for each time point. The spectra obtained were analyzed using MestReNova 
software (Mestrelab Research S.L., Santiago de Compostela, Spain). 
3.2.3. Kinetic Analysis 
 
We assumed the reactions followed first order kinetics. Natural logarithms of the estimated 
concentrations were represented as a function of time after enzyme addition and the rate constants 
fitted by linear regression from the slope of appearance or disappearance of the corresponding 
product or reactant. For stoichiometry purposes, the net balance in reactant or product 
ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ  ?ȴ ? ]) was calculated as the difference between the initial and final concentrations. 
Fractional changes (% Change) in the concentration of reactants (R) or products (P), as referred to 
the change concentration of the hypoxic marker (HM) were calculated using the equation:  
                                                           ?ܥ݄ܽ݊݃݁ ൌ   ?ሾோ௢௥௉ሿೣ ?ሾுெሿ ൈ  ? ? ?                                                               [1] 
  
3.3. Cellular studies of nitroimidazole bioreduction 
 
We investigated the biological reduction of nitromidazole compounds under different oxygen 
tensions and redox states using cultures of glioblastoma C6 cells. 
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3.3.1. Influence of the oxygen tension. 
 
C6 cells (ATCC/LGC Promochem, Barcelona, Spain) were grown to confluence (10-cm Petri dishes, 37 
oC, 5 % CO2/95 % O2 )ŝŶƵůďĞĐĐŽ ?ƐDŽĚŝĨŝĞĚĂŐůĞ ?ƐDĞĚŝƵŵ ?DD )ƐƵƉƉůĞŵĞŶƚĞĚǁŝƚŚ 5 % fetal 
bovine serum (FBS), 100 µg/mL streptomycin, 25 µg/mL gentamycin, 100 U/mL penicillin and 1 % 
fungizone. Prior to the experiment, cells were pre-incubated for 24h under the same oxygen 
concentrations used during the experiment. The medium was then replaced by DMEM containing the 
nitroimidazolyl derivatives (2.5 mM) and cells were incubated under the different oxygen tensions (0 
%, 1 %, and 21 %) for increasing times (3, 6 and 12 hours). Incubations in normoxic and hypoxic 
condition (21 % and 1 % O2 respectively) were carried out in an incubator where the ambient oxygen 
tension could be manipulated (Thermo Forma Series II Water Jacketed CO2 Incubator). Anoxic 
conditions (0 % O2) were achieved by adding deferroxamine (100 µM) to the incubation medium. At 
the end of the incubation, cells were frozen using liquid nitrogen, harvested and analyzed by high 
resolution magic angle spinning (HR-MAS). Each incubation condition was replicated three times. 
3.3.2. Influence of the redox state. 
 
C6 cells were grown to 90% confluence in DMEM medium as previously described. DMEM was then 
replaced by DMEM without glucose, L-glutamine, phenol red, sodium pyruvate and sodium 
bicarbonate (Sigma, D5030), but containing 2.5 mM Misonidazole analog and i) 5 mM glucose 
(condition 1); ii) 5 mM glucose and 10 mM lactate (condition 2); iii) 5 mM glucose and 10 mM 
pyruvate (condition 3) and iv) 5 mM glucose and 2 mM cysteine (condition 4). At the end of the 
incubation period (24 h), cells were frozen using liquid nitrogen, harvested and pellets were studied 
with HRMAS. Perchloric acid extracts of the individual cells pellets were prepared, neutralized with 
KOH, lyophilized, and resuspended in H2O, as previously described (34,40). Extracts were analyzed for 
glucose and total glutathione concentrations. Each condition was replicated three times. 
3.3.3. Metabolite measurements 
  
Metabolites were determined in the perchloric acid extracts of the cellular pellets. Glucose 
concentration was measured spectrophotometrically (340 nm, 37 °C) by using conventional 
enzymatic end point methods coupled to NAD(P)H production or consumption (18). Briefly, glucose 
was determined by an end point assay coupled to the NADPH production, using hexokinase and 
glucose-6-phosphate dehydrogenase.  
Total gluathione was measured spectrophotometrically using an enzymatic cycling method (412 nm, 
37 °C). Briefly, it was determined through a kinetic assay in which catalytic amounts (nmoles) of GSH 
cause a continuous reduction of DTNB to TNB and the oxidized glutathione (GSSG) formed is recycled 
by glutathione reductase and NADPH. The GSSG present will also react to give a positive value in this 
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reaction (9). Spectrophotometric measurements were performed in 96-well polypropylene plates 
using a vertical spectrophotometer (Spectramax TM 340 PC, Molecular Devices, Sunnyvale, CA).  
3.3.4. High resolution magic angle spinning (HR-MAS) 
 
MR acquisitions were performed in an 11.7T (500.13 MHz) Bruker AVANCE wide-bore spectrometer 
equipped with a triple-nuclei (1H, 13C, and 31P) HR-MAS probe. Cell pellets were harvested and placed 
ŝŶĂ ? ?ʅůŝƌĐŽŶŝƵŵKǆŝĚĞƌŽƚŽƌ ?ƌƵŬĞƌŝŽƐƉŝŶ ?ZŚĞŝŶƐƚĞƚƚĞŶ ?'ĞƌŵĂŶǇ )ĂĚĚŝŶŐ ? ?A?ůŽĨ2O and 1 
mM of TSP as an internal reference. The filled rotor was then transferred to the HR-MAS probe 
where sample was spun at 5 kHz, 4 ºC. 1D 1H HR-MAS spectra were acquired using Carr-Purcell-
Meiboom-Gill (CPMG) sequence with 2 s water presaturation, 1 ŵƐĞĐŚŽƚŝŵĞ ?ʏ )ĂŶĚ  ? ? ?ŵƐƚŽƚĂů
spin WƐƉŝŶƌĞůĂǆĂƚŝŽŶĚĞůĂǇ ? ?Ŷʏ ) ? ? ? ? ? ?ĚĂƚĂƉŽints, 10 KHz spectral width and 512 scans (172). 
3.3.5. Spectral analysis 
 
The spectra obtained were analyzed using MestReNova software (Mestrelab Research S.L., Santiago 
de Compostela, Spain). Hypoxic marker signals were normalized to the total choline signal (G= 3.2 
ppm).  
3.4. In vivo studies of nitroimidazole reduction 
 
We further investigated the potential of nitroimidazole derivatives to be used in vivo as hypoxia 
markers using 1H MRS.  
3.4.1. Tumor model 
 
The experimental protocols used in these studies were approved by the appropriate institutional 
review committees and met the guidelines of the appropriate government agency; all efforts were 
made to minimize animal suffering. Animals were housed in a humidity- and temperature-controlled 
room on a 12h light/dark cycle, receiving water and food ad libitum. The C6 glioma model was 
implemented essentially as described previously (58). C6 cells were grown to confluence (10-cm Petri 
dishes, 37 oC, 5% CO2/95% O2) in DMEM supplemented with 5% FBS, 100 µg/mL streptomycin, 25 
µg/mL gentamycin, 100 units/mL penicillin and 1 % fungizone, harvested and kept on ice until 
injection. Nude mice (NU/NU, 20-25 g), were implanted subcutaneously with C6 cells (approx. 106) in 
flanks. Tumors were allowed to grow up to 1 cm diameter and then studied by MR.  
3.4.2. In vivo Magnetic Resonance  
 
MRI and MRS studies were performed in vivo during tumor development, using a 7.0 T Bruker 
Pharmascan system equipped with a gradient insert of 90 mm diameter (maximum intensity of 360 
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mT/m). A 1H rat brain receive-only surface coil (circularly polarized) with integrated combiner and 
preamplifier, no tune/no match (T11257V1) in combination with the actively detuned transmit-only 
resonator (T11070V1) (Bruker BioSpin MRI GmbH, Rimpar, Germany) was employed. Data were 
acquired with a Hewlett-Packard console running Paravision software (Bruker Medical GmbH, 
Ettlingen, Germany) operating on a Linux platform. Animals were anesthetized by inhalation with 2-3 
% of isofluorane in an induction chamber (1 L min-1) and maintained with 2 % of isofluorane in 
different gases, at the same flow, through a nose mask. Three different isofluorane carriers were 
employed for volume selected spectroscopic measurements: 100 % oxygen (n=6), air (n=7) or a 
mixture of 10 % O2 and 90 % N2 (n= 7). In the case of spectroscopic imaging (MRSI), 100 % oxygen 
(n=2) and air (n=2) were used. Animals were taped down into the holder to minimize breathing-
related motion, and then placed in a heated probe, which kept the core body temperature at 37oC. 
The physiological state of the animal was monitored throughout the experiment with a Biotrig 
physiological monitor (Bruker Medical), using the respiratory rate and body temperature. This setup 
was then positioned in the isocenter of the magnet. 
Anatomical T2 weighted (T2W) spin-echo images were acquired using Rapid Acquisition Relaxation 
Enhancement (RARE) sequences (75,76) and the following parameters: repetition time (TR) = 3000 
ms, echo time (TE) = 60 ms, RARE factor = 8, 3 averages, field of view (FOV) = 38 x 38 mm, acquisition 
ŵĂƚƌŝǆ ?Dƚǆ )A? ? ? ?A? ? ? ? ? ? ? ?A? ? ? ?ʅŵ2 in plane resolution, slice thickness = 1 mm and 16 slices. In 
vivo 1H MR single voxel spectra were obtained using a Point Resolved SpectroScopy (PRESS) 
sequence with a Variable Pulse Power and Optimized Relaxation Delays (VAPOR) (43) module to 
suppress water signal intensity. Briefly, a voxel of 5x5x5 mm3 was placed inside the tumor by using 
T2W images as localization. First- and second-order shims were automatically adjusted with 
FASTMAP application in a sufficiently large voxel (6x6x6 mm3). The spectrum was acquired with the 
following parameters: TR = 3000 ms, TE = 35 ms, number of scans = 128, total acquisition time = 6 
min 48 s.  
After the basal spectrum, the animal was removed from the magnet but maintained in the same 
position in the holder. An aqueous solution of the oxygen reporter MISO (1M) and TSP (2M) was 
intratumoraly injected (50 µL) using a gas tight syringe with a custom-made fine sharp needle (26G 
#7803 W04; Hamilton, Reno, NV). Anatomical images and spectroscopy acquisitions as described 
previously were repeated. The evolution of the injected reporters was monitored during at least one 
hour using 1H MRS. The first spectrum (reference) was obtained 20 minutes after the injection. At the 
end of the experiment, animals were sacrificed. 
For in vivo MRSI, the multivoxel acquisition protocol was similar to previously described. Briefly, 
animals were located in the magnet holder and anatomical T2W spin-echo images were acquired 
using RARE as explained above. The B0 field distribution in a large voxel (40x40x40 mm
3) containing 
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the whole tumor was acquired (FieldMap) and used for the shim adjustment. Briefly, the tumor was 
localized with a coronal T2W sequence, and first- and second-order shims adjusted with MAPSHIM 
application in a sufficiently large voxel containing tumor and healthy tissue. MRSI was performed in 
two spatial dimensions, exciting a PRESS selected volume of 8 × 8 × 4 mm. Acquisition parameters 
were: FOV = 32 × 32 mm, MRSI matrix = 8 × 8 zero-filled to 32 × 32, TR = 1500 ms, TE = 19.3 ms and 
500 transients acquired during 12.6 min. Water suppression was performed with a VAPOR sequence. 
After basal spectrum, the animal was removed and injected as previously described. The animal was 
then introduced again in the magnet and the process repeated. The evolution of the injected 
reporters was monitored during at least two hours after injection. The first MRSI study (used as 
reference in map calculations) was obtained 30 minutes after the injection. At the end of the 
experiment, animals were sacrificed.  
3.4.3. Data analysis  
 
Metabolites from the in vivo MRS acquisition were quantified by measuring the area of the peaks 
with the software MestReNova (Mestrelab Research S.L., Santiago de Compostela, Spain) for single 
voxel spectroscopy. Spectroscopic images were reconstructed and quantified by using 3DiCSI 1.9.9 
software (Hatch Center for MR Research, Columbia University, New York, NY). Statistical calculations 
were performed by using GraphPad Prism (GraphPad Software, Inc. La Jolla, USA). Chemical shift for 
each resonance is referred to the protons signal of the methyl group of the total creatine at 3.02 
ppm. The integral of D/^K ?Ɛ protons marked as Ha and Hb (Table 5), TSP (0 ppm) and lipids (1.5-0.7 
ppm) signals were measured at each time after drug administration. The percentage of TSP and 
hypoxia marker relative to lipid signal was calculated using the following equation: 
 
                                                          ?ܥ݋݉݌݋ݑ݊݀ ൌ ஺௥௘௔௖௢௠௣௢௨௡ௗ஺௥௘௔௟௜௣௜ௗ ݔ ? ? ?ሾ ?ሿ 
 
For single voxel experiment, these values were represented against time and the trendline in each 
case was calculated by least-square non-linear regression (GraphPad Software, Inc. La Jolla, USA). 
Only those regressions with r2 > 0.8 were accepted for further analysis. The percentage of the hypoxic 
marker and TSP signals remaining at the end of the experiment was calculated by the ratio of the 
signal obtained 60 and 20 min (reference) after the injection of the compounds.  
In the case of MRSI, only those voxels with signal to noise ratio (SNR) equal or bigger than 2 were 
taken into account. The values compared where those obtained 70 and 30 min after the intratumoral 
injection. Parametric color-based maps were generated by using Matlab (2008a, The Mathaworks 
Inc., Natick,  Massachusetts, US ) based home made software. 
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3.4.4. Statistical analysis 
 
Statistical significance was assessed using ƐƚƵĚĞŶƚ ?Ɛ ƚ- test and analysis of variance (ANOVA). The 
assumption is that inhaled gas is the independent variable while the percentage of the hypoxic 
marker and TSP signals remaining at the end of the experiment are the dependent variables.  
3.5. DOCENT  
 
We also propose here a new methodology to assess tumoral response to hyperoxic gas breathing 
without the need to administer exogenous probes. These experiments were performed in the 
Sowthwestern Medical center of the University of Texas at Dallas during a short term visit associated 
to my predoctoral fellowship. 
3.5.1. Tumor model 
 
The experimental protocols used in these studies were approved by the appropriate institutional 
review committees and met the guidelines of the appropriate government agency; all efforts were 
made to minimize animal suffering. Animals were housed in a humidity- and temperature-controlled 
room on a 12-h light/dark cycle, receiving water and food ad libitum. Two sublines of the Dunning 
prostate R3327 adenocarcinoma were selected: HI, a moderately well-differentiated subline, 
hormone-insensitive and relatively slow growing with a tumor volume doubling time (VDT) of 9 days; 
and AT1, a faster growing, poorly-differentiated subline with a VDT of 4.4 days (85). Pieces of freshly 
excised donor tumor tissue were implanted subcutaneously in the thigh of adult male Copenhagen 
rats (~250 g, Harlan, Indianapolis, IN), as described in detail previously (70). Tumors were 
investigated by MRI when small (<3 cm3) or large (>3 cm3). Seventeen HI tumors, including 8 smaller 
(size range 0.7  W 2.6 cm3) and 9 larger (range 3.6  W 7 cm3), and 16 AT1 tumors, including 9 smaller 
(range 0.75  W 2.2 cm3) and 7 larger (range 3.1  W 5.8 cm3) were examined. Prior experience allows 
tumors to be classified according to the expected level of baseline hypoxia, response to hyperoxic gas 
breathing and tumor growth delay in response to irradiation (25,227). Specifically, Type 1 tumors are 
hypoxic, do not respond to hyperoxic gas breathing and respond poorly to irradiation, as exemplified 
by larger Dunning prostate R3327-AT1 tumors. Type 2 tumors exhibit baseline hypoxia, but are 
responsive to hyperoxic gas breathing with enhanced radiation response (e.g., larger HI tumors and 
smaller AT1 tumors) and Type 3 tumors show minimal baseline hypoxia and are inherently 
responsive to radiation (e.g., smaller HI). 
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3.5.2. In vivo Magnetic Resonance Imaging  
 
MRI experiments were performed using a Varian Unity Inova® 4.7 T horizontal bore system (Palo 
Alto, CA) equipped with actively shielded gradients (150mT/m). Each rat was maintained under 
general gaseous anesthesia (1.5 % isoflurane in air, 1 L/min). The rat body temperature was 
maintained using a warm water blanket. The tumor was placed inside a size-matched single-turn 1H 
volume coil. Imaging protocol is summarized in Figure 9. Briefly, following shimming on tissue water 
signal to a typical linewidth of 50 Hz, a Spin Echo Multiple Slice (SEMS) sequence was applied to 
acquire T1 maps under air breathing (baseline) with the TR arrayed as 9 values from 100 ms to 3500 
ms, TE = 20 ms, FOV = 40 u 40 mm, Mtx= 64 u 64, slice thickness = 1.5 mm and 3 slices separated by 
1 mm space in 10.5 min. Baseline T2* maps were obtained with a Gradient Echo Multiple Slice 
(GEMS) sequence using TR = 195 ms, TE arrayed as 7 values from 7 ms and spacing 6 ms and the 
same spatial resolution as for T1 maps in 3 min. Slice positioning and geometry were maintained 
through all the subsequent experiments. Then a series of 5 T1 weighted images (T1W), with TR = 30 
ŵƐ ?dA? ?ŵƐ ?DƚǆA? ? ? ?ǆ ? ? ? ?ƐůŝĐĞƚŚŝĐŬŶĞƐƐA? ? ? ?ŵŵ ?ĨůŝƉĂŶŐůĞ ?ɲ )A?45q, acquisition time = 3 s, 
and T2* weighted images (T2*W), with TR = 150 ms, TE = 20 ms, Mtx = 128 x 128, slice thickness= 1.5 
ŵŵ ?ɲA? ? ?q, acquisition time = 19 s, spoiled gradient-echo images were acquired in an interleaved 
fashion, as baseline. At this point, the breathing gas was changed to carbogen (1 L/min) and a series 
of 20 interleaved T1W and T2*W images were acquired over 10 min. Finally, T1 and T2* values were 
measured again during carbogen inhalation. 
 
 
 
Figure 9. Scheme of gas breathing sequence and image acquisition protocol for BOLD /TOLD experiment.  
Sequence acquisition times were as follow, T1 map = 10.5 min, T2* map= 3 min, T1 weighted (T1W) = 3s and T2* 
weighted (T2*W) = 19 s.   
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3.5.3. Data analysis  
 
Data analysis was performed using IDL-based software. Briefly, signal intensity (SI) in the initial five 
T1W or T2*W images (during air breathing) was averaged to obtain mean baseline images. 
Normalized image SI values were then calculated on a voxel-by-voxel basis by following the 
expression: 
             ?ܵ ܫሺ ? ሻ௜ǡ௠ǡ௡ ൌ  ௌூ೔ǡ೘ǡ೙൫ ? ௌூ೔ǡ೘ǡ೙ఱ೔సభ ହ ? ൯ כ  ? ? ?െ  ? ? ?ሾ ?ሿ 
 
where i is the image number, m and n are the image matrix, and SI is the voxel intensity. T1 values for 
a given voxel were obtained by fitting the signal intensities corresponding to nine delay values to a 
three-parameter least squares curve, using a Levenberg-Marquardt algorithm. T2* values for a given 
voxel were obtained by fitting an exponential model of signal decay curve. Common voxels (typically, 
1300 to 2500 depending on tumor size) were compared under carbogen and air breathing and 
differences calculated:  
            ȟ1 = (R1 CB - R1 AirሻƬȟ2* = (R2*CB - R2*Air)                                            [4] 
 
3.5.4. Statistical analysis 
 
Statistical significance of changes in SI in T1W and T2*W images and relaxation rates was assessed 
using GraphPad Prism (GraphPad Software, Inc. La Jolla, CA) or Statview (SAS Inc., Carey, NC) 
ƐŽĨƚǁĂƌĞǁŝƚŚŽŶĞǁĂǇEKsĂŶĚ&ŝƐŚĞƌ ?ƐProtected Least Significant Difference (PLSD) Žƌ^ƚƵĚĞŶƚ ?Ɛ
t-tests. Data are presented as mean ± standard error (SE). 
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4.1. Reduction of Nitroimidazolyl derivatives as detected by MRS 
4.1.1. Synthesis and characterization of new 2-nitroimidazolyl derivatives as hypoxia 
markers  
 
The synthetic route to dimethyl 2-(2-Nitro-1H-imidazol-1-yl)succinate 4 (NISUCA) is depicted in 
Scheme 2. Briefly, 2-nitro-1H-imidazole (1) reacted with a slightly excess of dimethyl 
acetylenedicarboxylate in acetonitrile (MeCN) at 80 °C, giving Z/E-isomers 2 (61%) and 3 (17%). The 
structures of 2 and 3 were well characterized by spectroscopic methods and confirmed by X-ray 
diffraction analysis (164). Subsequent attempts to reduce of the double bond of compounds 2 and 3 
using palladium on carbon and ammonium formate or Wilkinson catalyst were unsuccessful and the 
starting materials recovered. Compound 4 was only isolated, in 80% yield, by selective reduction of 2 
with borane in tetrahydrofuran at 0 °C. No evolution of 3 was observed, and compound 2 was 
exclusively reduced. Isomerization of compound 3 to 2 was achieved by refluxing 3 with 4-
toluenesulfonic acid in MeCN. Hydrolysis of 4 was carried out under neutral, acidic, or alkaline media. 
Retro-Michael reaction products were isolated under basic conditions whereas, in acidic medium, 
degradation products of the compound 4 were observed. Finally, compound 5 was only obtained by 
stirring 4 in water at room temperature for more than 30 days, but not as a totally pure sample. 
It is well known that 2-nitroimidazolyl derivatives are sensitive to low oxygen concentrations due to 
their selective reduction and subsequent trapping in hypoxic regions. This property is dependent of 
the redox potential. Thus, the first step to know whether compound 4 could be used as hypoxia 
marker was to determine its redox potential. Compound 1 was used as a reference. Table 6 
summarizes the redox potential (E1/2) of compounds 1 and 4 obtained using cyclic voltammetry. E1/2 is 
defined as  
                                                               ܧଵ ଶ ? ൌ ா೎೛ାாೌ೛ଶ  ሾ ?ሿ 
where Ecp is E of cathodic peak and, Eap is E of anodic peak. 
Table 6. Redox potential of 2-Nitroimidazole compounds and NISUCA. 
Compound/Medium 
DMF, Bu4N
+
BF4
-
 Phosphate buffer 0.1 M, pH = 7.2 
Ecp
a
 (V) E1/2
a
 (V) Ecp
b
 (V) E1/2
b
 (V) 
2-Nitroimidazole (1) -0.872 
-1.973 
- 
-1.900 
-0.698 
-1.287 
- 
- 
NISUCA (4) -0.989 
-1.953 
-0.934 
-1.888 
-0.615 
-1.138 
-0.551 
- 
Cyclic voltammograms (CV) of all compounds were carried out (6 mM solutions) in two different media.  The 
scan rate was 100 mV s
 W1
. CV analysis was supported using a glassy carbon electrode (GCE), Ag/AgCl, Cl
 W
/3 M 
KCl, and platinum as reference and auxiliary electrodes, respectively.  
a
 Aprotic media: Dimethylformamide (DMF), 0.1 M Bu4N
+
BF4
 W
. 
b
 Protic media: phosphate buffer pH 7.2. 
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As indicated in Table 6, the reduction potential of the nitro group of molecules 1 and 4 was medium 
dependent. We aimed to study the formation of the nitro radical anion in a medium where it was 
kinetically stable (aprotic solvents). Cyclic voltammetry of 4 in aprotic solvent represented two 
reversible reduction peaks, one of them at less negative potential, E1/2 =  W0.934 V, probably 
corresponding to the formation of the nitro radical anion (reversible according to CV). Irreversible 
reduction at  W0.872 V was observed for the 2-nitroimidazole 1 containing active hydrogens. In order 
to determine values for the redox potentials in a pH range simulating biological conditions, we 
investigated additionally the corresponding potentials in protic medium,  such as phosphate buffer 
(pH 7.2), Compound 4 exhibited E1/2 =  W0.551V.  
4.1.2. Enzymatic reduction in a cell free system 
 
To investigate the mechanism of nitroimidazole reduction, and the main determinants affecting the 
reduction rate, we choose the NADPH:cytochrome P450 reductase as in vitro enzymatic system. 
Several studies have shown that this is the main enzyme involved in the in vivo reduction of 2-
nitroimidazoles but the mechanism remained elusive yet (3,91,216) .  
First, we assessed the stability of the reactants and products to non enzymatic catalysis under the 
same conditions used later for the enzymatic analysis. In the absence of enzyme, NADPH showed a 
spontaneous disappearance without concomitant NADP+ generation, either when present alone or in 
a mixture with other compounds. Reduced glutathione (GSH) was stable when alone, but it depicted 
a small spontaneous reduction in presence of NADPH. NADP+ and GSSG were stable both alone and 
in presence of other compounds. The enzymatic system had no effect on the stability on these 
compounds. To avoid contamination from the spontaneous reactions, NADPH and GSH consumptions 
were measured through the production of NAPD+ and GSSG since these compounds were unaffected 
in the absence of P450ase. 
In order to characterize the main determinants of nitroimidazole reduction, representative reactions 
of Misonidazole (MISO) with P450ase were investigated under different conditions. A summary of 
the results is depicted in Table 7. MISO was not reduced spontaneously under any of the investigated 
conditions (Table 7, conditions b). Therefore, the enzymatic system is a necessary requirement for 
this reaction to take place (Table 7, conditions a). The reduction only took place when NADPH was 
present in the medium (Table 7, conditions 1a, 5a and 6a). GSH alone was not able to reduce MISO 
(Table 7, condition 3a), but when added to NADPH, increased drastically the MISO reduction rate 
(Table 7, condition 6a), as compared to that found with NADPH alone (Table 7, condition 1a). NADP+ 
nor GSSG, alone (Table 7, conditions 2a and 4a) or in combination with other compounds (Table 7, 
conditions 6a, 7a and 8a), depicted any additional affect in the MISO reduction rate. 
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Table 7. Principal determinants of MISO reduction.  
The reactions were followed by 
1
H MR as indicated in Methods. Phosphate buffered (75 mM, pH= 7.7, 37
o
C, 
10% D2O) reaction mixtures containing MISO (5 mM), NADPH (15 mM), NADP
+
 (15 mM), GSH (10 mM), GSSG 
(5mM) and NADPH:cytochrome P-450 reductase (0.2 U/ ml) where appropriate, were prepared in 5 mm MR 
tubes using TSP (1 mM) as an internal reference.  
 
To gain insight into the mechanism of reduction of the different hypoxic markers, we tested four 
nitroimidazolyl derivatives (Figure 8), both commercially available (MISO analog and PIMO) and 
synthesized in our lab (NIMAC and NISUCA). Briefly, we used buffered aqueous reaction mixtures (75 
mM phosphate buffer, pH= 7.7, 22 oC), containing NADPH (15 mM), TSP (1 mM), D2O (10%), GSH (10 
mM, where indicated), P450ase (0.2 U/ml, where indicated), GR (1 U/ml, where indicated), and the 
corresponding nitroimidazole derivative (5 mM). Experiments were performed under four 
characteristic environments: normoxia; anoxia; normoxia plus GSH and anoxia plus GSH. The 
reactions were triggered by the addition of the enzymatic system to the MR tube containing the 
appropriate reactants. The time course of the reaction was followed by 1H MRS, thus allowing 
monitoring simultaneously the time evolution of the different metabolites observed. Figure 10a 
illustrates at increasing time points, the reduction of MISO in presence of NADPH and GSH under 
normoxic conditions. MISO (orange ) ? EW,  ?ƌĞĚ ) ĂŶĚ '^, ?Ɛ  ?ƉƵƌƉůĞ )resonances could be clearly 
detected at the beginning of the experiment (Figure 10a, time 10 min, lower spectra). These 
resonances decreased with increasing time (Figure 10a, upper spectra), while NADP+ (blue) and GSSG  
(green) resonances increased. 
Condition NADPH NADP
+
 GSH GSSG Enzyme 
MISO 
reduction rate 
Subsidiary reactions 
1a + - - - + Slow Fast NADPH disappearance 
1b + - - - - No reaction Slow NADPH disappearance 
2a - + - - + No reaction  
2b - + - - - No reaction  
3a - - + - + No reaction Slow GSH disappearance 
3b - - + - - No reaction Slow GSH disappearance 
4a - - - + + No reaction  
4b - - - + - No reaction  
5a + - + - + Fast 
Fast NADPH disappearance.  
Fast GSH disappearance 
5b + - + - - No reaction Slow NADPH disappearance 
6a + - - + + Slow Fast NADPH disappearance 
6b + - - + - No reaction Slow NADPH disappearance 
7a - + + - + No reaction 
 
7b - + + - - No reaction 
 
8a - + - + + No reaction  
8b - + - + - No reaction  
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Figure 10. Kinetics of MISO reduction by P450ase under aerobic conditions in the presence of GSH. 
a) Relevant regions of the 
1
H MR spectra of the reaction mixture at increasing times. b) Monoexponential 
decays of MISO, NADPH and GSH and monoexponential increase of NADP
+
 and GSSG concentrations with time 
after the addition of P450ase. c) Changes with time of the newly generated resonances M2 and M3. MISO 
(orange), NADPH (red), GSH (purple), NADP
+
 (blue) and GSSG (green). 
 
The observed changes in concentration were fitted to a monoexponential function, (Figure 10b), and 
the apparent reaction rate constants determined as indicated in Methods. The MISO reduction rate 
constant was greatly increased in the presence of GSH, becoming 29 and 20 times faster in normoxia 
and anoxia, respectively (Figure 11a). Notably, molecular oxygen had a drastically smaller impact in 
the reduction rate of MISO, increasing the reduction rate 2 times only in anoxia with respect to 
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normoxia, (Figure 11a, insert). Overall, there is a tendency towards a faster reduction rate in anoxia 
than in normoxia. GSH also increased the production rate of NADP+, but not as much as with MISO 
(Figure 11b). It is worth mentioning that there was a mismatch between the reaction rates of the 
redox pair GSH/GSSG (Figure 11b). 75% of reduced glutathione is recovered as the oxidized 
counterpart at the end of the reaction, being the reduction rate of GSH twice faster than the 
formation rate of GSSG under normoxic conditions. It is also important to note that some new 
resonances appear as singlets around 7 ppm (Figure 10a, M2 and M3).  Their time course is complex, 
following an exponential growth (M2, Figure 10c) or a biphasic response with initial increases 
followed a decrease (M3, Figure 10c). These new signals appear only when GSH is present in the 
reaction mixture. 
  
Figure 11. Apparent rate constants for the reduction of MISO under different conditions.  
a) Apparent rate constants for the reduction of MISO. b) Apparent rate constants for GSH consumption and 
GSSG or NAPD
+
 production. Normoxia (blue), normoxia + GSH (green), anoxia (red) and anoxia + GSH (purple). 
 
Similarly to MISO, PIMO (gray), NADPH (red ) ĂŶĚ '^, ?Ɛ  ?ƉƵƌƉůĞ )resonances decreased with time 
after the addition of the enzyme (Figure 12a), whereas NADP+  ?ďůƵĞ )ĂŶĚ'^^' ?Ɛ ?ŐƌĞĞŶ )resonances 
increased. Changes in concentration with time were fitted to a monoexponential equation (Figure 
12b) and rate constants derived. There was a cohort of new resonances appearing in the 6.90-7.05 
ppm interval (P2-P5, Figure 12a). Some of them reached a maximum at different times and then 
began to decrease (P3-P5, Figure 12c) whereas others followed an exponential growth along the 
entire reaction time (P2, Figure 12b). It should be highlighted here that these signals appeared only 
when GSH was present in the medium and that they do not originate from any of the well known 
components of the reaction mixture. GSH induced ĂŵĂƌŬĞĚŝŶĐƌĞŵĞŶƚŝŶW/DK ?ƐƌĞĚƵĐƚŝŽŶƌĂƚĞ ? ? ? ?
times in normoxia and 60 times in anoxia, as compared with the rates obtained with NADPH alone 
(Figure 13a). Notably, there was little difference when carrying the reaction in presence or in the 
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absence of oxygen (Figure 13a, insert). As previously observed, GSH increased the rate of NADP+ 
generation, but not as much as during the reduction of MISO. There was a mismatch between the 
rate constants of disappearance of GSH and appearance of GSSG, the rate of disappearance of GSH 
being 24 and 13 times faster than the rate of appearance of GSSG under normoxic or anoxic 
conditions, respectively (Figure 13b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Reduction of Pimonidazole with P450ase under aerobic conditions in the presence of GSH. 
a) Relevant regions of 
1
H MR spectra from the reaction mixture at increasing times. b) Monoexponential 
decreases of PIMO, NADPH and GSH and monoexponential increases of NADP
+
 and GSSG after addition of the 
enzyme. c) Changes with time of the newly generated resonances P2, P3, P4 and P5 originated during the 
reaction. PIMO (gray), NADPH (red), GSH (purple), NADP+ (blue) and GSSG (green). 
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Figure 13. Apparent rate constants for the reduction of PIMO under different conditions.  
a) Apparent rate constants for the reduction of PIMO. b) Apparent rate constants for GSH consumption and 
GSSG or NAPD
+
 production. Normoxia (blue), normoxia + GSH (green), anoxia (red) and anoxia + GSH (purple). 
 
In the case of the nitroimidazole derivative NIMAC, synthesized in our labs, its resonances (gold, 
ŽƌĂŶŐĞ ? )ĂƐǁĞůůĂƐƚŚŽƐĞŽĨEW, ?Ɛ ?ƌĞĚ )ĂŶĚ'^, ?Ɛ ?ƉƵƌƉůĞ )ĚĞĐƌĞĂƐĞĚǁŝƚŚƚŝŵĞǁŚĞƌĞĂƐƚŚŽƐĞŽĨ
NADP+ (blue) and GSSG (green) increased (Figure 14a). We fitted the changes in concentration after 
enzyme addition to a first order kinetic model (Figure 14b), determining the corresponding apparent 
rate constants for the different molecules observed. In contrast to previously tested hypoxia 
markers, a new pair of doublets appeared close to NIMAC original resonances (Figure 14a, orange 
squares and 14c orange), following an exponential growth. These doublets are present both in 
absence and presence of GSH, although in the presence of GSH their production remained smaller. 
Similarly to the previous nitroimidazoles, a new group of resonances in the 6.7-7.0 interval ppm 
appeared only when GSH was present (Figure 14a & c, NM2-NM6). They followed complex kinetics, 
some increasing very early in the experiment; achieving a maximum at different times during the 
reaction course and finally decreasing towards the end (NM4 and NM6, Figure 14a & c). Others 
appeared later in the time course of the reaction and grew then exponentially until the end (NM3 
and NM5, Figure 14a & c).  
GSH increased the reduction rate of NIMAC between 3 (normoxia) and 6 (anoxia) times as compared 
to NADPH alone (Figure 15a). These increases were not as prominent as those found in the other 
commercial hypoxia markers investigated. This could be explained because of the higher NIMAC 
reduction rate when GSH was not present in the medium, approximately 20 times faster when 
compared to MISO or PIMO. The presence of oxygen resulted in opposite effects in the reduction 
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rate of NIMAC than those previously described. Its absence decreased 30% the rate constant for 
NIMAC reduction when no GSH was present (Figure 15a insert). In contrast, anoxic conditions 
increased by 20% the reduction rate of NIMAC with respect to normoxia, when GSH was present 
(Figure 15a). Similarly to the other commercial hypoxia markers, NADP+ generation (and NADPH 
consumption) was exacerbated in presence of GSH (Figure 15b). There was also a mismatch between 
GSH consumption and GSSG production, becoming 7 and 3 times faster in normoxia and anoxia 
conditions respectively (Figure 15b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Reduction of NIMAC with P450ase under aerobic conditions in the presence of GSH.  
a) Relevant regions of the 
1
H MR spectra of the reaction mixture at increasing times, b) Monoexponential 
decays of NIMAC, NADPH and GSH and monoexponential increase of NADP
+
 and GSSG concentration after the 
addition of the enzyme, c) Changes with time of the newly generated resonances (NM2, NM5, NM6). 
Assignments are proposed based on theoretical calculations of the chemical shift of the possible reaction 
products. NIMAC (orange), NADPH (red), GSH (purple), NADP+ (blue) and GSSG (green). 
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Figure 15. Apparent rate constants for the reduction of NIMAC under different conditions.  
a) Apparent rate constants for the reduction of NIMAC. b) Apparent rate constants for GSH consumption and 
GSSG or NAPD
+
 production. Normoxia (blue), normoxia + GSH (green), anoxia (red) and anoxia + GSH (purple). 
 
Finally, the same set of experiments were performed with an additional 2-nitroimidazole derivative 
synthesized in our labs (155), NISUCA. As observed before, NISUCA (pink), NADPH (red) and GSH 
(purple) diminished with time (Figure 16a) while NADP+ (blue) and GSSG (green) increased. These 
compounds followed apparently first order kinetics and the corresponding apparent rate constants 
were calculated by fitting the changes in concentration to a monoexponential equation (Figure 16b). 
The pattern of the new resonances arising during the reaction time course was more complex than in 
the aforementioned nitroimidazole derivatives. More specifically, new pairs of doublets appeared 
close to the original NISUCA signal (N2, Figure 16a & c) as with NIMAC. These were present both in 
presence and absence of GSH, although they became more abundant in the absence of GSH. As with 
other hypoxia markers, there was a group of resonances, both singlets (N3-N5, Figure 16a & c) and 
doublets (N6 and N7, Figure 16a & c) in the 6.8-7.1 ppm interval that only became visible when GSH 
was present in the incubation medium. Some of these new resonances increased at the beginning, 
reached a maximum and then decreased (N3, N5 and N6, Figure 16c) whereas others followed a 
hyperbolic growth (N4 and N7, Figure 16c). N2 reached a plateau level very early in the reaction and 
did not change significantly thereafter (Figure 16c). Notably, when GSH was not present, new singlet 
resonances were detected in the same spectroscopic area. They were different from those originated 
in the presence of GSH, depicting also a complex kinetic behavior as previously described. Molecular 
oxygen induced a small effect in the reduction rate of NISUCA under all the tested conditions (Figure 
17a). GSH increased approximately 3 times the reduction rate of NISUCA, both in normoxia and in 
anoxia. The effect of reduced glutathione in the reduction rate of the nitroimidazolyl derivative was 
smaller than with MISO and PIMO, but similar to NIMAC. This effect could also be explained due to 
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the high reduction rate found without GSH in the medium, which was around 80 times higher than 
with the commercial markers for hypoxia. As previously found with the other nitroimidazoles, 
NADPH consumption was increased when reduced glutathione was present in the reaction mixture 
(Figure 17b). As in previous cases, the apparent rate constants for GSH disappearance and GSSG 
appearance were mismatched (Figure 17b), being 4 and 20 times faster for GSH in presence and 
absence of oxygen ƌĞƐƉĞĐƚŝǀĞůǇ ? E/^h ?Ɛ ƌĂƚĞ ĐŽŶƐƚĂŶƚƐ ǁĞƌĞ ŚŝŐŚĞƌ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ŽƚŚĞƌ
nitroimidazolyl derivatives in all tested conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. NISUCA reduction in vitro with P450ase under aerobic conditions in the presence of GSH.  
a) Relevant regions of the 
1
H MR spectra of the reaction mixture at increasing times. b) Monoexponential 
decays of NISUCA, NADPH and GSH and monoexponential increase of NADP
+
 and GSSG with time after 
addition of the enzyme. c) Changes with time of the new generated resonances (N2, N3, N4, N5, N6 and N7). 
NISUCA (pink), NADPH (red), GSH (purple), NADP
+
 (blue) and GSSG (green). 
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Figure 17. Apparent rate constants for the reduction of NISUCA under different conditions 
a) Apparent rate constants for the reduction of NISUCA. b) Apparent rate constants for GSH consumption and 
GSSG or NAPD
+
 production. Normoxia (blue), normoxia + GSH (green), anoxia (red) and anoxia + GSH (purple). 
 
To investigate in more detail the role of GSH in the reduction process of hypoxic markers, the 
reactions were carried out in the presence of two enzymatic systems: P450ase and GR. This last 
system regenerated GSH levels as GGSG was formed and thus kept constant the GSH level during the 
entire time course of the reaction. For the commercial hypoxia markers MISO and PIMO, we found 
no significant changes in the reduction process under these conditions. However, with our home 
made NIMAC and NISUCA, the presence of GR approximately doubled their reduction rates both in 
absence and in presence of oxygen. Regarding the newly generated signals, their kinetic behavior did 
not change significantly in most of the cases. Only NISUCA depicted significant modifications. In this 
case, some of the signals that accumulated during the reaction (N7, Figure 16c) showed a decrease at 
certain stage when GR was present. Other signals, shifted from an increase and posterior decrease 
(N5, Figure 16c) to a continuous increase. To gain insight into the stoichiometry of the reduction, 
changes observed in GSSG and NADP+ concentrations were compared to those detected in the 
hypoxia probe. NADPH and GSH were not used for this purpose since they depicted spontaneous, 
non enzymatic disappearance, without concomitant NADP+ and GSSG production under the studied 
conditions. In the presence of reduced glutathione, the reduction of 1 mol of nitroimidazolyl 
derivative was accomplished with the oxidation of 1.5 to 2 mol of NADPH (which renders 2 electron 
per molecule oxidized) and 1 mol of GSH (with the concomitant liberation of 1 electron per molecule 
oxidized), resulting in a 4 to 5 electron reduction stoichiometry (Figure 18). No significant differences 
were found between the normoxic and anoxic conditions.  
0
20
40
60
80
100
120
140
160
A
p
p
a
re
n
t 
ra
te
  c
o
n
st
a
n
t 
(m
in
-1
 x
 1
0
4
) 
NISUCA 
NISUCA + Air NISUCA + GSH + Air NISUCA + N2 NISUCA + GSH + N2
0
50
100
150
200
250
300
GSH GSSG NADP+
A
p
p
a
re
n
t 
ra
te
  c
o
n
st
a
n
t 
(m
in
-1
x
 1
0
4
) 
a b 
a b 
 
 
82 
 
R
e
su
lt
s 
Figure 18. Stoichiometry of the reduction reaction. 
a) Mol of GSSG produced by mol of NITRO consumed. b) Mol of NADP
+
 produced by mol of NITRO consumed. 
 
 
It should be stressed here that if we follow the total glutathione concentration (GSH + GSSG) by their 
Hb proton, which depict the same chemical shift (Table 5), its equivalents remained constant along 
the reaction coordinate. However, if we used Ha protons, which have different chemical shifts for 
GSH and GSSG (Table 5), we found that total glutathione decreased at the beginning of the reaction 
and then increased. But not all the GSH present originally was recovered as GSSG, indicating the 
existence of GSH/GSSG sink. Usually, only around 50% of the parental GSH is recovered as its 
oxidized counterpart at the end of the reaction. In the case of NISUCA, this recovered percentage 
increases reaching 75% of the initial GSH. These evidences revealed the formation GSH-
nitroimidazole derivative conjugate during the reduction reaction. These adducts may be formed by 
ƚŚĞůŝŶŬŽĨƚŚĞƚŚŝŽůŐƌŽƵƉŽĨ'^,ƚŽĞŝƚŚĞƌƚŚĞŝŵŝĚĂǌŽůĞƌŝŶŐŽƌƚŚĞŶŝƚƌŽŵŽŝĞƚǇŽĨƚŚĞƉƌŽďĞ ?'^, ?Ɛ
ĂŶĚ'^^' ?Ɛ,b are located far away from thiol group and a link trough it would not affect significantly 
the chemical shifts of the Hb resonances. However, the Ha ?Ɛ are closer to the thiol group and thus, 
any chemical change in this moiety will be reflected in the chemical shift of these resonances. 
Importantly, new groups of multiplets were detected between 3.30 to 3.05 ppm (Figure 16a and 
Figure 19a). In order to characterize the influence of the initial concentration of hypoxia probe in the 
reduction rate, the reactions were implemented in the presence of different initial concentrations of 
MISO and NIMAC (Figure 20). The kinetics were followed for two hours to avoid interferences from 
the changes in other factors occurring at later stages (i.e, total consumption of NADPH or GSH). In 
the case of MISO (Figure 20a), reduction rate increased linearly with initial hypoxia marker 
concentration in both normoxia (r2 = 0.9984) and anoxia (r2=0.9468). However, NIMAC (Figure 20c) 
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followed an asymptotic growth reaching the maximum at 10 mM. The oxygen tension did not play an 
important role when NIMAC concentration was lower than 5 mM. At higher concentrations, the 
anoxic condition resulted in higher reductions rates. The impact of GSH in the reduction rate of MISO 
and NIMAC was assayed using a similar strategy. In this case, reduction rates increases with GSH 
concentration reaching a plateau at 10 mM. No significant differences were found between anoxia 
and normoxia for none of the hypoxia marker probes (Figure 20 b & d).  
Figure 19. Newly generated resonances during the reduction of NISUCA with NADPH:cytochrome P450 
reductase under aerobic conditions in presence of GSH. 
a) Newly generated signals (blue square) for Ha protons of GSH when forming an adduct with NISUCA. b) Newly 
generated signals for Ha and Hb of NISUCA when forming and adduct with GSH. 
  
4.1.3. Enzymatic reduction in a cell containing system 
 
Next step was to test whether 1H MRS was a suitable technology to detect hypoxia in vivo using 2-
nitroimidazolyl derivatives. The four hypoxia markers previously investigated in cell free systems 
were incubated with C6 glioma cells, with different environmental oxygen concentrations. At the end 
of the incubation period, cell pellets were harvested and studied by HR-MAS. Figure 21 showed a 
representative 1H HR-MAS spectrum from cell pellet incubated for six hours with NISUCA under 
hypoxic conditions (1% O2 ) ?dŚĞƌĞƐŽŶĂŶĐĞƐĨƌŽŵE/^h ?Ɛ,a and Hb can be conveniently observed 
between 7.2 and 7.7 ppm. The reductiŽŶŝŶƚŚĞŝŶƚĞŶƐŝƚǇŽĨE/^h ?ƐƌĞƐŽŶĂŶĐĞƐ ?ŽƌĂŶŐĞƌĞĐƚĂŶŐůĞƐ )
for decreasing environmental oxygen tensions is depicted in the insert of Figure 21. PIMO rendered 
similar results, as shown in Figure 22. There was a significant decrease in the intensity of the hypoxia 
marker resonances (insert Figure 22, orange rectangles) between normoxic (blue) and hypoxic (red) 
or anoxic (green) conditions, indicating larger reductions under hypoxic or anoxic conditions. 
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Figure 20. Influence of the initial concentrations of nitroimidazole and GSH in the reduction rate of the 
hypoxia marker in the presence of oxygen and under hypoxic conditions. 
a) Initial reduction rate of MISO for different initial MISO concentrations. b) Initial reduction rate of MISO for 
different initial concentrations of GSH. c) Initial reduction rate of NIMAC analog for different initial 
concentrations of NIMAC. d) Initial reduction rate of NIMAC for different initial concentrations of GSH.  
Figure 21. 
1
H MR spectra of representative C6 cell pellets after six hours incubation with NISUCA under 
different oxygen tensions. 
Blue arrow indicates total choline signal used for normalization. Insert shows an amplification of the spectral 
region (7.7 to 7.1 ppm) where NISUCA resonances (orange rectangle) appear. Normoxia (blue), hypoxia (red) 
and anoxia (green). 
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The amount of hypoxia marker remaining at the end of the incubation with C6 cells was quantified 
relative to total choline resonance (3.20 ppm, blue arrow in Figures 21 & 22), which did not change 
during the course of the experiment. A statistically significant decrease (P < 0.05, ONE way ANOVA) 
in the relative intensity of NISUCA resonances was found for decreasing oxygen tensions (Figure 23a). 
In the case of MISO, a decrease in the biomarker probe relative to choline was observed for 
decreasing oxygen tensions (Figure 23b), although it did not reach statistical significance (P = 0.08, 
one way ANOVA). NIMAC (Figure 23c) showed a statistically significant reduction (P < 0.05, t-test) in 
signal intensity when comparing normoxic and hypoxic conditions. Finally, PIMO showed a 
statistically significant difference (P < 0.05, one way ANOVA) between different incubation conditions 
(Figure 23d). In this case, it is important to remark that hypoxia caused a larger decrease in signal 
intensity than anoxia.  
  
Figure 22. 
1
H MR spectra of C6 cell pellet after six hours of incubation with PIMO under different oxygen 
tensions. 
The blue arrow indicates the total choline resonance used for normalization. Insert shows a region of the 
spectra where PIMO resonances (orange rectangle) appear. Normoxia (blue), hypoxia (red) and anoxia (green).  
 
To explore the influence of the redox state and GSH in the reduction rate of MISO in vivo, C6 cells 
grown to confluence were incubated under normoxic conditions with a special medium: DMEM 
without glucose, L-glutamine, phenol red, sodium pyruvate and sodium bicarbonate. This medium 
was supplemented with 2.5 mM MISO and i) 5 mM glucose (condition 1); ii) 5 mM glucose and 10 
mM lactate (condition 2); iii) 5 mM glucose and 10 mM pyruvate (condition 3) and iv) 5 mM glucose 
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and 2 mM cystine (condition 4). 1H HR-MAS spectra obtained from the cell pellets at the end of the 
incubations showed that MISO was clearly visible in conditions 1 and 2, whereas it depicted a much 
smaller signal intensities in conditions 3 and 4 (Figure 24a). The quantification was performed as 
described earlier using the total choline resonance as internal reference. Results showed marked 
changes in hypoxic marker content between the different incubation conditions (Figure 24b). Total 
GSH content in cells, measured in a separate cohort of pellets, indicated more than twice GSH 
concentration in cells in conditions 3 and 4 compared with conditions 1 and 2 (Figure 24c). There was 
a strong negative linear correlation (R2 > 0.97) between the amount of MISO detected in the cell  
pellets and the total glutathione  content  (Figure 24d). 
 
  
Figure 23. Influence of the environmental oxygen tension in the reduction rate of different hypoxia markers. 
Percentage of remaining NISUCA (a), MISO (b), NIMAC (c) and PIMO (d) resonances detected in pellets of C6 
glioma cells, with respect to total choline, after 6 h of incubation under different oxygen tensions. Normoxia 
(blue), hypoxia (red) and anoxia (green). Lower oxygen tensions result in smaller amounts of probe remaining 
at the end of the reaction, revealing normally increased reduction rates for lower oxygen concentrations. 
 
4.1.4. In vivo experiments 
 
Finally, we aimed to investigate whether the combination of nitroimidazolyl derivatives and 1H MRS 
could be used to detect changes in tumor oxygenation in vivo. For this purpose, we used a tumor 
model where C6 glioma tumors were grown in the flank of nude mice. This allowed the direct 
intratumoral injection of a mixture of MISO and TSP using a very fine needle (26G) to minimize tumor 
damage. TSP was employed as a reference molecule since it has a similar molecular weight (172.3 
g/mol) than MISO (187.2 g/mol), appears far away from the MISO resonances (around 0 ppm) in the 
1H spectra where it is clearly detectable, and its in vivo behavior is not sensitive to oxygenation. Thus, 
its disappearance with time will provide a measurement of natural in vivo clearance of the 
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administered preparation. The hypoxia marker would suffer however, in addition to natural 
clearance, the disappearance due to in vivo reduction, the rate of which is oxygen dependent. Tumor 
oxygenation was modified by changing the proportion of oxygen in the anesthetic carrier gas 
breathed by animals: 100% O2 in group 1 or hyperoxic condition; 21% O2 (air) in group 2 or normoxic 
condition and a mixture of 10% O2 and 90% N2 in group 3 or hypoxic condition. 
 
Figure 24. Influence of redox state in the reduction rate of hypoxic markers. 
The redox state of C6 glioma cells was manipulated by incubating the cells with DMEM without glucose, L-
glutamine, phenol red, sodium pyruvate and sodium bicarbonate but containing 2.5 mM MISO and either i) 5 
mM glucose (condition 1, blue); ii) 5 mM glucose and 10 mM lactate (condition 2, green); iii) 5 mM glucose and 
10 mM pyruvate (condition 3, yellow) and iv) 5 mM glucose and 2 mM cystine (condition 4, red). a) 
Representative regions of the 
1
H-MR spectra of cell pellets 24 h after of incubation showing MISO (left) and 
total choline (right) signals. b) Percentage of MISO, with respect to total choline, detected in after the 
incubation in different redox states. c) Reduced glutathione content after incubation. d) Negative correlation 
between MISO and GSH measured in C6 pellets (r
2
= 0.9679). 
 
TSP (purple) and MISO Ha and Hb resonances (orange) were clearly detected using localized 
1H MRS 
PRESS after intratumoral injection (Figure 25a). Signal intensity of the hypoxia marker (orange) and 
reference compound (purple) decreased with time (Figure 25b) whereas the methylene resonances 
from lipids (blue) did not change significantly during the entire experimental time. On these grounds, 
MISO and TSP resonances were quantified relative to the methylene lipid signals. Under these 
conditions, D/^K ?Ɛ ĂŶĚ d^W ?Ɛresonances decreased following apparent first order kinetics (Figure 
25c).  
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In analogy to previous hypoxia measurements with fluorinated nitroimidazoles (4), we calculated for 
each animal the percentage of the remaining signal one hour after the injection with respect to the 
signal intensity detected immediately after the administration of the probe. When comparing these 
values in the different groups of animals, the percentage of remaining MISO decreases (P > 0.01, one 
way ANOVA) with the percentage of oxygen in the breathing gas (Figure 26). There was also a small 
decrease in TSP signal with decreasing oxygen content in the breathing gas, but these changes did 
not reach statistical significance (P = 0.46). When comparing percentage of remaining compound at 
the end of experiment between MISO and TSP, they turned out to be very similar for the 
hyperoxygenated group (Figure 26). Differences between both compounds increased in normoxic 
group and are more accentuated in hypoxic group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. In vivo time course of MISO and TSP disappearance after intratumoral injection. 
a) PRESS spectra of the C6 cell implanted tumor obtained before (top) and after (bottom) the injection 
(multisite) of a mixture of MISO (orange) and TSP (purple). Lipids signal are marked in blue. b) Time course of 
disappearance of MISO and TSP resonances as detected with 
1
H MRS PRESS. c) In vivo monoexponetial decays 
of the MISO and TSP resonances, relative to the methylene lipid resonance. 
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Figure 26. MISO and TSP disappearance in vivo.  
Amount of MISO (a) and TSP (b) remaining in the tumor (median values) at one hour relative to the amount 
detected immediately after the injection of the compounds in hyperoxigenated (100% O2), normoxic (21% O2) 
and hypoxic (10% O2) tumors.  
 
 
 
Nevertheless, it is widely accepted that tumors present highly heterogeneous pO2 distribution, 
highlighting the importance of spatial information. To this end, maps of the MISO and TSP 
percentage remaining 70 min after injection were calculated by acquiring multivoxel spectroscopy 
data of tumors treated as previously described for animal breathing pure oxygen and air (Figure 27).  
Obtained values were similar to those found with single voxel spectroscopy. Tumors depicted 
statistically significant differences in the percentage of MISO signal remaining in animal breathing 
pure oxygen (mean = 78 ± 1) and air (mean = 58 ± 1), whereas it was not the case for the % of TSP 
(mean = 72 ± 2 in both cases (Figure 28). As we observed with single voxel spectroscopy, the 
percentage of remaining compound between MISO and TSP turned out to be similar under hyperoxic 
conditions while differences were more accentuated in normoxic situation. On these grounds it 
seems reasonable to propose that maps of MISO intensity at different oxygen tensions provide a 
suitable indicator of the local tumoral oxygenation. It is also important to remark that there is no 
spatial correlation for the values obtained for MISO and TSP in a voxel by voxel way 
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Figure 27. Maps of in vivo evolution of MISO and TSP.  
Percentage of MISO and TSP remaining in the tumor at 70 minutes relative to the amount detected 30 minutes 
after intratumoral injection: a) % of MISO in animal breathing pure oxygen. b) % of TSP in animal breathing 
pure oxygen. c)% of MISO in animal breathing air and d) % of TSP in animal breathing air. 
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Figure 28. MISO and TSP disappearance in vivo by 
1
H MRSI.  
Scatter plot of the amount of MISO (left) and TSP (right) remaining in the tumor at 70 minutes relative to the 
amount detected 30 minutes after the injection of the compounds in hyperoxygenated (blue) and normoxic 
(red) tumors.  
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4.2. Endogenous contrast agents as detected by MRI 
 
The spectroscopy method described above is not devoid of limitations including the mandatory use 
of an external contrast agent, the need of direct intratumoral injection and the reduced temporal 
and anatomical resolution. To overcome these shortcomings, we implemented a novel imaging 
approach to monitor the response of tumors to pO2 modulation. We proposed to take advantage of 
the paramagnetic properties of molecular oxygen and deoxyhemoglobin as surrogate markers of 
tumor pO2. Molecular oxygen acts as a T1 contrast agent whereas deoxyhemoglobin behaves as a T2* 
contrast agent. The method developed here improved considerably many of the limitations of the 
spectroscocopic approach, including higher temporal and spatial resolution, avoiding the 
administration of the exogenous probe. Briefly, two rat prostate tumor types, noted for differential 
growth rates, vascular development and oxygenation (25,227), were employed as models. Both T1 
and T2* values and SI in T1W and T2*W images were compared while the animal model breathed air 
or carbogen in vivo. 
 
4.2.1. BOLD and TOLD 
 
During air breathing (baseline), MRI SI was generally stable  ?ŵĞĂŶȴ^/ŝŶd2*W and T1W images were 
very similar, the differences being less than 1%, Figures 29-32), despite considerable heterogeneity, 
particularly in T2*W images (Figure 33). Increased SI in T2*W images was usually significant within 30 
seconds after switching gases, normally reaching a stable plateau within two minutes for both small 
and large HI tumors and small AT1 tumors (Figures 29-31, a-c). Large AT1 tumors often showed a 
transient increase with return to baseline after two to six minutes (Figure 32c). BOLD response to 
carbogen was heterogeneous with focal signal changes ranging from plus 100% to minus 40% respect 
to baseline SI, but the mean value for each adjacent slice was quite uniform (Figures 29-32 c). T1W 
signal response was considerably smaller under these data acquisition parameters and the response 
tended to be slower, but remained still significant (Figures 29-32, d-f).  
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Figure 29. Response of T1- and T2*-weighted image signal intensity to carbogen challenge in a small Dunning 
prostate R3327-HI tumor. 
Normalized spin echo planar T2*W cross-sectional images of a representative tumor acquired while breathing 
(a) air (baseline), and (b) carbogen (image selected to show maximum change). c) Mean BOLD (normalized SI) 
response in three adjacent image slices (o, ȴ, ) and mean over whole tumor (). Corresponding normalized 
T1W gradient echo images of the tumor acquired breathing (d) air and (e) carbogen. f) Mean variations across 
the tumor of normalized 'SI vs. time (TOLD response). Heat scale bar shows % increase or decrease and linear 
scale = 5 mm. Tumor size = 2.1 cm
3 
Figure 30. Signal response to carbogen challenge in a large Dunning prostate R3327-HI tumor.  
Data correspond to Figure 29 but for a larger HI tumor (5.7 cm
3
). The BOLD response was significant, but 
considerably lower than in the smaller HI tumor, whereas the TOLD response was quite similar to smaller 
tumors.  
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Figure 31. Signal response to carbogen challenge in a small Dunning prostate R3327-AT1 tumor.   
Data correspond to Figure 29, but in a smaller AT1 tumor (0.75 cm
3
). The BOLD and TOLD responses were both 
considerably lower than in the smaller HI tumor. 
Figure 32. Signal response to carbogen challenge in a large Dunning prostate R3327-AT1 tumor.  
Data correspond to Figure 29, but in a larger AT1 tumor (5.8 cm
3
). The BOLD and TOLD responses were each 
considerably smaller than in the other tumors.  
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Figure 33. 
1
H MRI of Dunning prostate tumors.  
Representative baseline T2*W and T1W images are shown for each tumor type. Images: Upper row shows small 
tumors and lower row large tumors.  
 
Small HI tumors generally showed the largest BOLD response with mean signal increase ranging from 
6 to 57% within 1 minute of changing gas and settling on a plateau of 4% to 66% enhancement (mean 
21 + 7%, Table 8), as shown for a typical tumor (Figure 29 a-c). TOLD response was smaller and initial 
rapid response was followed by continued increase over 10 minutes reaching 4 to 16 % (e.g., Figure 
29 d-f). The mean response of three adjacent image slices was highly consistent (Figure 29f). Large HI 
tumors showed a smaller T2*W response (Figure 30c), but T1W response (3 to 9%) approached that 
of the smallest tumors (Figures 29 & 30 f). Small AT1 tumors responded rapidly in both T1W and T2*W 
images with little further change after 2 minutes. There was obvious heterogeneity with greatest 
response close to the tumor periphery in both T1W and T2*W images (Figure 31). Large AT1 tumors 
showed particularly small BOLD and TOLD response (Figure 32 c & f).  
Each tumor type showed highly consistent responses and mean time courses are presented for both 
BOLD and TOLD experiments (Figure 34) and summarized in Table 8. Noting the initial rapid dynamic 
response leading to stable plateau, the data in Table 8 show tŚĞŵĞĂŶǀĂůƵĞƐĨŽƌȴ^/ĐŽŶƐŝĚĞƌŝŶŐŽŶůǇ
the last ten measurements during carbogen breathing. Mean changes in SI T1W and T2*W images of 
small HI tumors (known to be well oxygenated) were significantly greater than in small or large AT1 
tumors (p<0.05). The T1W image response was also significantly different between large HI and large 
AT1 tumors (Table 8).  
 
T
2
*- weighted                 T
1
-weighted                        T
2
*- weighted                T
1
-weighted    
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Table 8. BOLD and TOLD signal responses to carbogen challenge in groups of Dunning prostate 
R3327 tumors of different sizes. 
 
Tumor K> ?йȴ^/ ? ?ƌĂŶŐĞ TO> ?йȴ^/ ? ?ƌĂŶŐĞ 
Small HI (n=8) 21 ± 7 a  / 0.4-65% 8 ± 1 a / 4-16% 
Small AT1 (n=9) 8 ± 2 / 0.6-20% 4.5 ± 0.9 / 1-8% 
Large HI (n=5) 7 ± 1 / 4-13% 5 ± 2 b / 3-9% 
Large AT1 (n=7) ± 0.7 / -0.6-5.6% ± 0.3 /0.7-2.7% 
  a
 p<0.05 versus small and large AT1; 
b
 p<0.05 versus large AT1. 
 
 
Figure 34. Comparison of BOLD and TOLD response in groups of Dunning prostate tumors. 
a) Dynamic normalized T2*W signal response to carbogen challenge in the four different groups of tumors. b) 
Corresponding T1W signal responses. S (small HI; n= 8), ¡ (small AT1; n= 9),  (large HI; n= 6), o (large AT1; 
n= 7). 
 
T1W and T2*W signal responses were well matched with a general trend of larger TOLD response 
being associated with larger BOLD response (Figure 35a). Considering the 29 tumors, where T1W and 
T2*W signal responses were evaluated, the linear correlation coefficient showed R
2>0.75 (p<0.0001), 
which strengthened considerably for HI tumors alone (R2>0.85), although it was weaker for AT1 alone 
(R2>0.53).  
4.2.2. R1 and R2* changes during hyperoxigenation 
 
To investigate the origin of the changes in SI, R1 and R2* maps, we evaluated 27 tumors during air 
and CB breathing (Figure 36 & 37) and the corresponding mean values are presented in Table 9. R2* 
ranged from 28 to 108 s-1 and changed significantly for many individual tumors, although did not 
become significant among the groups of tumors (Table 9 ) ?dŚĞƌĞǁĂƐĂĐŽƌƌĞůĂƚŝŽŶďĞƚǁĞĞŶȴ^/ ŝŶ
T2 ?tŝŵĂŐĞƐĂŶĚȴZ2* irrespective of tumor type and size (R2>0.48), which improved to R2>0.55 for 
AT1 tumors alone. A very similar result was observed if the percentage change in R2* was considered 
instead of the aďƐŽůƵƚĞȴZ2* value. Baseline R1 ranged from 0.389 to 0.711 s-1 (Table 9). No apparent 
Air Carboge
n 
Air Carbogen 
a b 
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ĐŽƌƌĞůĂƚŝŽŶ ǁĂƐ ĨŽƵŶĚ ďĞƚǁĞĞŶ ȴ^/ in T1t ƐŝŐŶĂů ĂŶĚ ȴZ1 (R2<0.1 for each tumor type). A strong 
ĐŽƌƌĞůĂƚŝŽŶ ǁĂƐ ŽďƐĞƌǀĞĚ ĨŽƌ ȴZ1 ǀƐ ? ȴZ2* for HI tumors (R2>0.67), but AT1 tumors showed no 
obvious trend (R2<0.25; Figure 35b). R1 and R2* values were very tightly correlated  during CB and air 
breathing , as expected since changes in relaxation values due to hyperoxigenation were relatively 
small (e.g., R2*(AT1) R
2>0.98; R1(AT1) R
2>0.98; R2*(HI) R
2>0.71; R1 (HI) R
2>0.8). Mean R1 and R2* values were 
not significantly different except for big HI tumors, as shown in Table 9.  
 
Figure 35. Correlation of TOLD and BOLD response to carbogen challenge.  
ŽŵƉĂƌŝƐŽŶ ŽĨ d ?  ?භ ) ĂŶĚ ,/  ?ȴ) tumors showed distinct trends for the group of 29 tumors. a) Signal 
enhancement showed a linear correlation for all tumors (R
2
>0.75), which was even stronger for HI tumors 
alone (R
2
>0.85). b) Mean change in R1 was closely reflective of R2* for HI tumors (R
2
>0.67), but showed no 
obvious relationship for the AT1 tumors.  
 
Table 9. Mean relaxation rates in groups of tumors to breathing air or carbogen 
   
Tumor (n) R2* air R2* CB ȴZ2* R1 air R1 CB ȴZ1 
HI (small) (5) 66.5 ± 6.5 
c 
(42-82) 
65.5 ± 7.8 a 
(42-85) 
-1.1 
0.45 ± 0.02 
(0.39-0.51) 
0.45 ± 0.02 a 
(0.41-0.51) 
0.005 
HI (large) (8) 43.9 + 4.4 
(34-72) 
38.4 + 2.0 
(34-48) 
-5.5 
0.51 + 0.01 
(0.47-0.46) 
0.55 + 0.01 
(0.46-0.61) 
0.039 
AT1 (small) (8) 64.4 ± 7.9
 a 
(28-108) 
64.3 ± 8.3 a 
(27-110) 
-0.1 a 
0.52 ± 0.04 
(0.44-0.71) 
0.51 ± 0.03 
(0.41-0.65) 
-0.007 a 
AT1 (large) (5) 56.3 ± 4.7 
(44-69) 
58.2 ± 4.6 a 
(44-70) 
1.9 a 
0.46 ± 0.03 
(0.41-0.53) 
0.46 ± 0.03 a 
(0.42-0.54) 
0.001 a 
  
(ȴR = RCB  W Rair); all data presented as mean + SE (s-1)with range in parentheses; (n) represents number of 
tumors; 
a
 p<0.05 vs. large HI tumors. 
 
 
 
 
 
 
a b 
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Figure 36. R2* response to carbogen challenge.   
R2* maps of small HI (a-c) and large AT1 (d-f) tumors respectively, when the rats were breathing air (a, d) or 
carbogen (b, e), together with difference maps 'R2* (s-1) = R2*Air  W R2*CB (c, f). 
 
Figure 37. R1 response to carbogen challenge.   
R1 maps of a small HI (a-c) and a large AT1 (d-f) tumor when the rats were breathing air (a, d) or carbogen (b, e) 
together with difference maps 'R1 (s-1) = R1 Air  W R1 CB (c, f).  
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4.2.3. Tumor stratification with DOCENT 
 
There was little overlap between magnitude of BOLD and TOLD responses, as shown in the box and 
whisker plots (Figure 38) when tumors were stratified as Types 1  W 3 as indicated in methods, based 
on anticipated hypoxia and response to radiation. Since both Types 2 and 3 are expected to respond 
well to radiation with hyperoxic gas breathing, a further classification considered Type 1 versus all 
others (Types 2 and 3 combined) in an effort to correctly assign tumors to potential response groups 
(Table 10 ) ?ZĞƐƉŽŶƐĞƚŚƌĞƐŚŽůĚƐǁĞƌĞĂƉƉůŝĞĚĂƐDĂũŽƌ ?K>ȴ^/AN ?A?ĂŶĚdK>ȴ^/AN ?A? )ŽƌDŝŶŽƌ 
 ?K>ȴ^/< ?A?ĂŶĚdK>ȴ^/<3%). All Type 1 tumors were correctly identified as hypoxic based on 
Minor signal enhancement. 8 out of 23 Type 2 or 3 tumors did appear to be hypoxic based on the 
BOLD threshold alone. However, the TOLD criterion left only 3 tumors as misidentified (apparently 
hypoxic), when actually responsive. If a 2% TOLD response was applied as the response threshold, 
then classification of responsive tumors improved, although now TOLD alone would misclassify some 
hypoxic tumors. 
 
 
Figure 38. Stratification of tumors in terms of expected radiation response.  
Type 3 tumors (small HI) are expected to show little hypoxia, large increase in response to breathing hyperoxic 
gas and good response to radiation. Type 2 tumors are expected to exhibit considerable hypoxia, which may be 
eliminated by breathing hyperoxic gas and hence generating good radiation response. Type 1 tumors are 
expected to be hypoxic and resist modulation by hyperoxic gas yielding poor radiation response. a) 
Stratification based on BOLD; b) Stratification based on TOLD.  
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Table 10. Predictive value for identifying tumor types. 
 
Magnitude 
of response
a
 
BOLD (T2*W) TOLD (T1W) 
Hypoxic
b
 Non-hypoxic or 
responsive
c
 
Hypoxic
b
 Non hypoxic or 
responsive
c
 
Major 0 14 0 19 
Minor 7 8 7 3 
 
a
 Major BOLD response threshold >6%; Major TOLD response > 3% 
b 
Hypoxic tumors (Type 1) are those which exhibit large hypoxic fraction, low mean pO2, do not respond to 
hyperoxic gas breathing and show no enhanced response to single high dose radiation, specifically large AT1 
tumors, based on published reports (25,124,227). 
c 
Non hypoxic or responsive tumors (Types 2 or 3) are those expected to have minimal hypoxic fraction or 
hypoxia, which is eliminated by hyperoxic gas breathing, and hence, these tumors respond to high dose 
radiation (25,124,227). 
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5.1. Nitroimidazolyl probes as hypoxia markers 
 
Despite their applications in nuclear medicine and histochemistry, nitroimidazole derivatives have 
not been previously used as 1H MR hypoxia markers. In particular, several 19F nitroimidazolyl 
derivatives have been proposed previously as PET, 19F-MRS and fluorescent histochemical probes for 
hypoxia. One of these molecules (SR-4554) entered recently in Phase I clinical trials (140-141). 
Nevertheless, the limited access to PET scanners and labeled radiofarmaceuticals, the usual lack of 
19F-MR capabilities in clinical scanners and the impossibility to use fluorescence bioimaging methods 
to examine deep regions in the human body, constitute important limitations to the widespread use 
of these compounds in the clinic. On these grounds, we decided to prepare here a new series of 
nitroimidazole derivatives that could be used in combination with more accessible preclinical and 
clinical 1H-MR instrumentation.  
5.1.1. Synthesis of new 2-nitroimidazole probes a hypoxic markers. 
 
Based in the previous experience of our laboratories (19,58,199), we choose to synthesize nitro 
analogs of the pH indicator ISUCA (2-(imidazol-1-yl)succinic acid) due to its favorable 
pharmacokinetic properties. However, the addition of 2-nitro-1H-imidazole to diethyl fumarate, 
under the conditions previously reported (62) did not yield the expected Michael adducts. We 
implemented then an alternative synthetic approach, as depicted in Scheme 2. It was not possible to 
obtain compound 5 in pure form, but compound 4 (NISUCA) was obtained in relatively high yield and 
was therefore further tested as a potential hypoxia marker. We also synthesized on our own and 
further investigated as an hypoxia probe methyl 2-(2-nitro-1H-imidazol-1-yl)acetate (NIMAC), the 
synthesis of which had been previously reported (115), but not used, to our knowledge, as a hypoxia 
probe.  
It is widely accepted that the biological activity of nitroimidazoles is dependent upon the reduction of 
the nitro group, a process originating the active species able to combine with biomacromolecules 
forming adducts that accumulate in the hypoxic environments (218). The first step consists of the 
single-electron reduction of the nitro group. Hence, the initial steps in the evaluation of NISUCA and 
NIMAC, as pO2 indicators, included the determination of their redox potential by cyclic voltammetry 
methods, using the corresponding 2-nitroimidazole 1 as a reference. We found a reduction potential 
of -0.511 V and -0.615/-1.138 V for NISUCA, in aprotic and protic medium, respectively (Table 6). 
These reference values were compared with those determined in the literature for other 
nitroimidazolyl derivatives (24), finding similar values to the other hypoxia markers in the case of 
NIMAC but not for NISUCA (Table 11). The differences found for NISUCA may be related to the 
different parameters assayed (E1/2 vs E respectively) and experimental conditions used in the 
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previous measurements (pH, aprotic medium, reference electrodes...). Notably, the use of hypoxia 
markers depicting different reduction potentials allowed us to investigate for the first time the 
relevance of this thermodynamic property in the in vitro and in vivo reduction rates of this type of 
compounds, comparing the obtained in vitro and in vivo reduction rate with their reduction 
potential.  
Table 11. Reduction potential of different nitroimidazole derivatives used as hypoxia markers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 E1/2: half wave potential. 
b
 E: reduction potential 
 
Table 11 indicates that all nitroimidazolic compounds depict in all cases more negative redox 
potentials than NADPH or GSH and are therefore suitable electron acceptors from these physiological 
electron donor molecules. However, we have shown that the presence of the nitroimidazolil 
derivative and NADPH or GSH, does not lead to an appreciable reduction of the probe, indicating that 
the different reduction reactions are not controlled thermodynamically by uncatalized electron 
transfers, but require the participation of an enzyme to control kinetically the reduction process. 
5.1.2. Main determinants of the enzymatic reduction of 2-nitroimidazole derivatives used 
as hypoxic markers.  
 
Once established that the control of the reduction rate involved kinetic, rather than thermodynamic 
control, we proceeded to investigate in more detail the determinants of the reduction rate of 
nitroimidazolyl derivatives. We performed a wide series of kinetic studies under different incubation 
conditions using initially a cell free, relatively simple, enzymatic reduction system. There is a large 
panel of enzymes that may be responsible of the nitroimidazole bioreduction; NADPH:cytochrome 
P450 reductase, cytochrome P450, xantine oxidase or DT-diaphorase. Joseph et al. (91) 
overexpressed P450ase and DT-diaphorase in monkey kidney cells. They found that 80 times 
augmented P450ase activity correlated with 5 to 7 fold increase in 2-nitroimidazole binding, whereas 
1000 fold activity increase of DT-diaphorase only correlated with a 1.5 growth in 2-nitroimidazole 
Compound Parameter pH Value (mV) Reference 
NISUCA E1/2 
a 7.2 -551 (155) 
2-Nitroimidazole E b 7.0 -418 (217) 
Misonidazole E1/2 
E 
7.2 
7.0 
-395 
-389 
(150) 
(217) 
Misonidazole analog E 7.0 -389 (217) 
NIMAC E 7.0 -355 (217) 
Pimonidazole E 7.0 -352 (217) 
NADPH E 7.0 320 (17) 
GSH E 7.0 240 (177) 
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binding. Aboagye et al. (3) used mouse liver microsomes and found that nitroimidazole reduction 
was markedly inhibited in air, in the absence of NADPH and in the presence of a P450ase inhibitor 
(TlCl3 4H2O). Taken together, these evidences indicated that P450ase is the dominant enzyme 
involved in the in vivo reduction of nitroimidazol based hypoxia markers, although it may not the 
only one (3). We decided, thus, to implement the P450ase system to investigate in vitro, in a cell free 
system under highly controlled conditions, the kinetic mechanism underlying the reduction of 
nitroimidazoles.  
At this point, it could be asked whether the differences in nitroreductase levels could be important 
factors determining the variations in nitroimidazole reduction and retention in tumor, rather than 
the environmental oxygen tension. However, a large study compared P450ase activity in 69 tumor 
cell lines (54), and found only relatively low activity for this enzyme compared with other reductases 
as DT-diaphorase and small variations across the different cell lines. Aboagye et al. (3) compared 
P450ase activity in mouse liver and various mouse and human tumors. It was high in liver 
microsomes but low and relatively constant (only 3-fold variation) in different tumors. These results 
suggest that the small variations in nitroreductase levels are not the main determinants of the large 
variations in nitroimidazole bioreduction observed in vitro and in vivo.  
Remarkably, our results showed that the oxygen tension by itself had also a small influence in the 
observed reduction rate of nitroimidazoles, whereas the GSH levels had a strong influence, increasing 
the rate of nitroimidazole reduction very significantly (Table 12). Based on our spectroscopic 
measurements, we propose that this increase in the reduction rate is mediate through the formation 
of an intermediate between nitroimidazole derivative and GSH. Furthermore, this adduct is formed 
through the union of the thiol group of GSH and either the imidazole ring or the nitro moiety of the 
probe.   
Table 12. Relative reduction rate constant of hypoxia markers. 
Hypoxic 
marker 
Condition 
Normoxia Anoxia 
Normoxia 
+ GSH 
Anoxia + 
GSH 
Normoxia 
+ GSH + GR 
Anoxia + 
GSH + GR 
MISO -0.7 ± 0.7 -1.0 ± 0.9 -15.8 ± 0.6 -16.7 ± 0.9 -13.7 ± 0.6 -12.7 ± 0.5 
PIMO -0.3 ± 0.5 -1.0 ± 0.6 -69 ± 2 -61 ± 2 -45 ± 3 -49 ± 2 
NIMAC -11.1 ± 0.4 -7.7 ± 0.8 -39 ± 1 -46 ± 1 -82 ± 2 -96 ± 4 
NISUCA -39 ± 1 -38 ± 1 -122 ± 6 -127 ± 9 ----- -299 ± 33 
Values are expressed in min
-1
 x 10
4
 
 
Notably, early studies by Whitmore and Varghese (204,218) demonstrated by HPLC the existence of 
conjugates between GSH and reduced products of nitroimidazole derivatives both in vitro and in 
chinese hamster ovarian (CHO) cells. Furthermore, it had been shown that treatment with MISO 
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under hypoxia results in GSH depletion (31). The precise mechanism for the formation of the adducts 
has not yet been established, although covalent bonding of GSH to either C4, C5 and both C4 and C5 
of the nitroimidazole ring have been detected both by MR and mass spectra (202). Studies 
concerning the metabolism of MIS0 by hypoxic rat livers showed that a MISO-glutathione conjugate 
was formed as a major metabolite, and that high doses of MIS0 result in depletion of hepatic 
glutathione (191,192). Furthermore, it was noted that formation of the MISO-GSH appears to 
correlate with the metabolic reduction of MIS0 (192).  
A key issue to be solved to fully understand the activity of these markers is the nature of the 
complexes formed between reduced nitroimidazole derivatives and cellular components. 
Immunohistochemistry studies clearly detect the presence of macromolecular adducts, since the 
lower molecular weight adducts would have been washed away during histological processing. The 
situation may result more complex if nitroimidazole markers are investigated by non histochemical 
techniques. For example, in the case of MRS detection, narrow peaks would only become visible if 
the adduct can tumble sufficiently rapid in the MR timescale; otherwise, a significant T2 reduction 
would lead to drastic resonance broadening, complicating the detection. Moreover, if the reduced 
drug reacts with immobilized macromolecules, it will become undetectable by MR after assuming the 
correlation time of the host macromolecule. In vivo 19F MR studies have shown, however, the 
presence of narrow resonances. Ex vivo experiments carried out at high field revealed shorter T2 
values for the reduced bound compounds, and the signal detected at later time points was 
composed of several unresolved peaks (180). A possible explanation for these findings is that the 
MR-visible complexes are formed with small sulfhydryl-containing peptides, such as glutathione, 
rather than with large macromolecules. These adducts would then be small enough to tumble rapidly 
in the magnetic field, generating sufficiently narrow resonances detectable by in vivo and in vitro 
MR. The elimination rate of these small adducts may be relatively high, so that, 6 h after drug 
administration, no MR signals are detected anymore within the tissue. Such a rapid elimination 
would not be possible for adducts formed with larger macromolecules. In this context, Hoff et al. (82) 
found an inverse relationship between MRS and flow cytometry measurements of EF5 in prostate 
tumors. They explained this by suggesting that nitroimidazole binding to macromolecular and non-
macromolecular cellular components is a competitive event between these two different binding 
sites. Summarizing, resonances observed by MRS shortly after drug administration are likely to be 
caused by nitroimidazole adducts with small molecules, such as reduced glutathione. The adducts 
observed immunohistochemically at later times may derive from coupling reactions with higher 
molecular weight cellular components, such as proteins or nucleic acids (174). 
There are several possibilities for the formation of adducts between nitromidazole derivatives and 
GSH, as indicated in Figure 39. Unfortunately, these molecules are highly unstable and it has not 
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been possible to isolate and characterize them individually. However, our MR study provides some 
useful information. We focused in the imidazolyc protons in the region 6.8-7.7 ppm, since they are 
inherently very sensitive to any change in the redox state of the nitro group and/or any change in the 
imidazole ring. In addition, only the imidazole derivative ĂŶĚƐŽŵĞEW, ?ƐƉƌŽƚŽŶƐĂƉƉĞĂƌ in this 
relatively uncrowded region of the spectra. Using this strategy, compounds I and II would appear as 
two doublets of the same intensity. Compounds III, IV, V and VI would appear as singlets. Compounds 
VII would give no signal in the aromatic region. Finally, compounds VIII would appear as several 
doublets (due to different conformational configuration possible).  We detect indeed some these 
resonances (Figures 10, 12, 14, 16 & 19b) but at present we are not be able to assign them 
unambiguously. However, it is possible to propose a tentative assignment based in theoretical 
calculations, previous studies (36,203) and the kinetic time course (Table 13).  
Considering this new information, it turns out that the previously presented scheme describing the 
biological reduction of nitroimidazole derivatives (Scheme 1) does not provide a completely correct 
interpretation of the reduction process. Our in vitro studies point towards a much more complex 
situation. Knox et al. (95) found 32 different reduction products of misonidazole by HPLC. In vivo, 
nitroimidazole based drugs eliminated by the renal pathway are basically excreted unchanged, with 
no metabolites detected by HPLC, either in urine or in plasma (1,2). Nevertheless, two steps have 
been proved to be certain, i) the formation of an anion radical at the beginning (137,213) and ii) that 
the reaction proceeds through hydoxilamine formation (44,95). Furthermore, some studies suggest 
that hidroxilamine is the terminal reactive species responsible for nitroimidazole in vivo activities 
(106,218) and a number of reaction mechanisms with cellular nucleophiles have been proposed 
(140). In this thesis we propose a new reduction mechanism that explains our present findings as 
well as those previously reported (Scheme 4).  
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a
 Roman numbers indicate the corresponding structure of Figure 39 to what these resonances were assigned.  
b 
Square brackets indicate the molecular structure originating the newly generated resonances as indicated  in 
Figure 16. 
c
 Newly generated signals depicted in figure 19b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Chemical structure of the possible adducts formed between reduced nitroimidazolyl derivatives 
and reduced glutathione (GSH). 
R1 would be different for each hypoxia marker used (see Figure 7).  
Table 13. Proposed assignment of the newly generated resonances of NISUCA conjugates 
originated during the bioreduction: theoretical and experimental chemical shift. 
Compound
a
 
Theoretical chemical shift (ppm) Experimental chemical shift (ppm) 
b
 
Ha Hb Ha Hb 
Ia 7.36 (d) 7.47 (d) 7.24 (d) 7.55 (d) [N2] 
Ib 7.03 (d) 6.80 (d) 
6.98 (d) 
6.897 (d) 
[N6] 
IIa 7.08 (d) 7.11 (d) 
IIb 7.04 (d) 6.84 (d) 
Ic 7.02 (d) 6.76 (d) 6.92 (d) 6.85 (d) [N7] 
IIIc - 7.10 (s) 
7.06 (s) [N4] 
Vc 7.70 (s) - 
IIIb - 6.78 (s) 
7.095 (s) + 7.085 (s) [N3] 
7.04 (s) [N5] 
 
IVa - 7.03 (s) 
IVb - 6.70 (s) 
Vb 7.28 (s) - 
VIa 7.64 (s) - 
VIb 7.09 (s) - 
VIIIa 5.62 (d) 5.27 (d) 5.46 (d), 5.43 (d) 
c 
5.37 (d) VIIIb 4.97 (d) 5.20 (d) 
 
I
a
 I
b
 I
c
 
VII
a
 VII
b
 VII
c
 VIII
a
 VIII
b
 
V
a
 V
b
 V
c
 VI
a
 VI
b
 
III
a
 III
b
 III
c
 IV
a
 IV
b
 
II
a
 II
b
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Scheme 4. Proposed mechanism for bioreduction of nitroimidazole derivatives with the 
concomitant participation of GSH and NADPH.   
1. Enzymatic reduction of nitro to nitroso with NADPH consumption. 2 .Non enzymatic reduction of nitroso to 
hydroxylamine with the formation of a Nitroimidazole-GSH adduct. 3. Enzymatic (up) and non-enzymatic 
(bottom) reduction of hydroxylamine to amine derivative with NADPH consumption (up) and/or Nitromidazole-
GS (bottom) adduct. 
 
The first intermediate of the bioreduction process: a nitroso derivative (reaction 1, Scheme 4). 
Metabolism of these compounds begins by the enzymatic reduction of the nitroimidazole derivative 
to the nitroso counterpart. This reaction is enzymatically catalyzed and proceeds with NADPH 
consumption. In fact, when no P450ase is present, the reaction does not progress. The 
disappearance of the probe occurs only when both P450ase and NADPH are present. GSH does not 
participate in this initial step since reduction proceed when GSH is not present and it is not able to 
reduce the hypoxic markers directly either alone or with P450ase, in the absence of NADPH (Table 7). 
The second step: the hydroxylamine intermediate (reaction 2, Scheme 4) 
 
The next step would be the non-enzymatic reduction of nitroso derivative to hydroxylamine with the 
concomitant oxidation of GSH to GSSG (reaction 2, Scheme 4). This reaction was proposed by Bump 
et al. (31) although it was not proved nor the exact mechanism elucidated. The reaction proceeds 
through the formation of an intermediate where GSH bonded covalently to the imidazole ring. We 
detected two new doublets closed to the original signals of NIMAC (NM2, Figure 14) and NISUCA (N2, 
Figure 16). We believe that these resonances belong to the nitroso derivatives, based on the 
theoretical chemical shift calculated for them by computational methods (Table 13). Indeed when 
GSH is not present, these resonances accumulate during the complete reaction time without any 
further transformation in both compounds. In contrast, when GSH is present, N2 reaches a plateau 
value early in the reduction process and, later, decreases slowly, indicating a net disappearance by 
transformation in a downstream intermediate. NM2 increases during the whole reaction. In both 
cases, the maximum concentration of N2 and NM2 is significantly smaller when GSH is present than 
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when it is not, suggesting that GSH favors the augmented disappearance of the nitroso intermediate. 
The nitroso derivatives cannot be further reduced in the absence of GSH, and can be considered as 
the final reduction products under these conditions. However, when GSH is present, the reduction 
can advance further and additional intermediates appear. The differences between NISUCA and 
NIMAC can be explained by the faster reduction rate of NISUCA, leading this compound to reach 
more rapidly a steady state of its reaction intermediates, whereas NIMAC is not able to reach this 
situation during the reaction time investigated. In both cases, the nitroso derivative generation was 
faster than its subsequent reactions, and a temporary accumulation can be detected. MISO and 
PIMO depicted a completely different situation. The fact that the nitroso derivative resonances from 
MISO and PIMO are not observed when GSH is not present is most probably due to a higher 
instability of their corresponding nitroso derivatives. When GSH is present, the generation of nitroso 
derivative is much slower than the posterior reactions of this reduced metabolite and thus no 
accumulation can be detected. This is in good agreement with the slower reduction constant found 
for MISO and PIMO under all tested conditions (Table 11).  
When GSH and GR were present, GSH becomes not limiting (since it is continuously regenerated 
from GSSG) and signal N2 achieved a maximum value early in the reduction process and then began 
to decrease. These results indicate unambiguously that GSH is involved in later reduction steps 
(reaction 3, Scheme 4) whose velocity will be faster with high GSH availability. This explains why, in 
presence of GR, N2 reached a maximum faster in the reduction process (reaction 2 is GSH 
dependent) and afterwards, decreased more rapidly (reaction 3 is also GSH dependent). On the other 
hand, NM2 increases during the whole reaction time. It is explained because the reduction of NIMAC 
is slower in all tested conditions (Table 12) and even in the presence of GR, NIMAC was not fully 
consumed during the reaction time investigated. Interestingly, PIMO and MISO, those with low 
reduction constant, showed a small decrease in their reduction rates with GR (Table 12). This may be 
due to the fact that GR consumes also NADPH to reduce GSSG to GSH causing a decrease in NADPH 
availability for the initial reduction step (nitro to nitroso derivative), diminishing then competitively 
the rate of the overall process. 
 
The third intermediate and final product: the amine derivative (reaction 3, Scheme 4) 
Afterwards, hydroxylamine can be reduced to amine either by enzymatic (reaction 3 up, Scheme4) or 
non enzymatic (reaction 3 bottom, Scheme 3) pathways, with the concomitant oxidation of NADPH 
and GSH respectively. We found several newly generated signals when GSH is present in the medium 
that could be attributed to the different adducts depicted in Figure 39. 
We propose that the reduction of the nitroso to hydroxilamine intermediates (reaction 2, Scheme 3) 
is the limiting step for the reduction of the nitroimidazole probes. The finding that the reaction is 
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inhibited at the nitroso derivative level in the absence of GSH and that the addition of GSH releases 
this inhibition and results in a high increase in the reduction rates under all the tested conditions 
provides a strong support to this concept. Furthermore, when GSH becomes not limiting (i.e., when 
GR is present), the reduction rate speeds up significantly with NIMAC and NISUCA. This is not the 
case with MISO and PIMO, due to the competition of GR and P450ase for NADPH in the in vitro 
situations tested. Several studies have reported the formation of conjugates between the chemically 
generated hydroxylamine derivatives and reduced glutathione, detected by 1H MR (201,202,204). 
Nevertheless, to our knowledge, no previous studies have addressed the reduction and the chemistry 
of nitroso derivatives, most probably because the high instability of these compounds. 
Previous studies proposed a mechanism for the addition of GSH to hydroxilamine (128,203). Based 
on these, the results presented above and the kinetics of formation of the different adducts, we 
propose the consensus reaction sequence depicted in Scheme 5. The previous proposals claimed that 
these types of reactions would occur in absence of P450ase and GSH, using hydroxyl anion (HO-) as 
the nucleophile. This process could well be the origin of the resonances we detected with NISUCA in 
absence of GSH. Also, Varghese et al. (203) detected small group of resonances between 5.3 and 5.5 
ppm, with the assigned to the different possible conformations of adduct VIII (Figure 39). We also 
detect such resonances in our spectra (Figure 19b) and our theoretical calculations predicted similar 
chemical shifts for these adducts (Table 13). The total reduction of nitroimidazole derivatives to their 
amine counterparts would require six electrons. However, our stoichiometry results reveal that 1.5 
to 2 molecules of NADPH and 1 molecule of GSH were oxidized to NADP+ and GSSG respectively, for 
every molecule of hypoxic marker consumed. This renders a 4 to 5 electron reduction under our 
conditions. These results are probably due to an incomplete reduction of the nitroimidazolyl 
derivatives. This interpretation is strongly supported by the fact that in all cases, at the end of the 
reaction, we still detect signals belonging to adducts between hypoxia marker and GSH.  
The cell free results described above contribute valuable new information to the previously accepted 
relationship between the environmental oxygen tension and the reduction rate of 2-nitroimidazolyl 
derivatives, currently the basis for their use as hypoxia markers. Our results reveal that bioreduction 
of these probes cannot be explained only on the basis of decreased oxygen tension. Indeed, a 
reduced or absent oxygen tension alone has been shown to be unable to reduce the probes in cell 
free systems. Present results show that NADPH, GSH, P450ase and eventually GR play, in addition, 
determinant roles during the reduction processes of these probes. However, these are not 
independent events and in vivo, a reduced oxygen tension leads generally to a more reduced redox 
state and concomitant NADPH and GSH accumulation. Thus, the bioreduction of nitroimidazoles 
appears not to be directly related to a lower oxygen level, but rather to the increases in NADPH and 
GSH triggered by hypoxia. 
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Scheme 5. Proposed reaction scheme for the formation of stable glutathione adducts of the nitroso 
derivatives of hypoxia probes. 
B represents any base. 
 
5.1.3. Reduction of hypoxic markers by C6 tumor cells 
 
Tumor cells are frequently observed to exhibit elevated levels of GSH (20,32,39,49,53,81,162,219). 
Furthermore, several studies demonstrated that low oxygen levels increased GSH concentration both 
ex vivo, in normal (11,22) and in tumoral cells (11,149) and in vivo, as in the liver of healthy chicken 
(14) and in radiation induced tumors (RIF-1) grown in mice (105). Additionally, it has been shown that 
GSH concentration is proportional to environmental oxygen tension in normal cells while tumoral 
cells show greater GSH levels at low oxygen tensions than normal cells (11). Increases in GSH levels 
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promote an increase in the reductive capacity in the tumor, mimicking hypoxic situations (84). In 
general, a direct correlation between GSH levels and the reductive capacity of different tissues has 
been reported (84).  
There is a variety of redox couples that work cooperatively in a cell to maintain the homeostasis of 
the redox environment including thioredoxins, NADPH, flavins, ascorbate, and others. However, the 
GSSG/GSH couple is the most abundant redox pair in cells and tissues (181). The intracellular 
concentration of GSH in eukaryotes is 1 W10 mM while GSSG is maintained within 1/100 W1/30 of the 
GSH levels (101). Nevertheless, high intertumor variability has been reported (68,73). Cysteine is 
another important thiol containing molecule that acts as redox buffer. Cysteine concentrations are 
typically much lower than GSH (1 to 10% of GSH) both in cell culture (214) and in normal tissues (96), 
but abnormally high levels have been found in vivo both in rodent tumors (96) and in human tumor 
biopsies (68).  
We tested whether the oxygen tension had an impact in the ex vivo metabolism of nitroimidazolyl 
derivatives in cell cultures. Our results clearly showed that the remaining amount of initial hypoxia 
marker detectable after six hour of incubation decreased with oxygen availability, indicating 
increased reductive metabolism (Figure 22). Both hypoxic (1% O2) and anoxic (0% O2) conditions 
resulted in measurable decreases in the amounts of all nitroimidazolyl derivatives investigated. As 
expected, those probes with slow in vitro reduction rates, MISO and PIMO, were detected, at higher 
concentrations (8 to 18 % of total choline signal) compared with those that exhibited higher 
reduction constants, NIMAC and NISUCA (4 to 10 % of total choline signal) in all tested conditions. 
We characterized the impact of the redox state in the normoxic metabolism of these compounds by 
changing the reductive capacity in the incubation medium. For that purpose, we added GSH to 
incubation medium. However, GSH is taken only in small amounts by cells (109) and no appreciable 
changes were detected.  Then, MISO was incubated in C6 cells in normoxia within oxidative 
conditions (glucose, glucose + lactate) and reductive conditions (glucose + pyruvate, glucose + 
cysteine). It should be noted that pyruvate is a precursor for the biosynthesis of glutathione through 
oxidative metabolism in HepG2 cells under normoxic conditions (178), preventing the loss of GSH and 
the reduction in the GSH:GSSG ratio of swine liver after hemorrhagic shock (135). Increased cysteine 
uptake and GSH synthesis under hypoxia in glioma cells have been reported (149). Total glutathione 
levels were measured as an indicator of the redox state of the cell. Glucose alone and in combination 
with lactate resulted in low levels of GSH and a decrease in the reduction of the hypoxic marker 
(Figure 23). On the other hand, pyruvate and cysteine had the opposite effect, increasing both total 
GSH and the reduction of nitroimidazolyl derivatives. Nitroimidazolyl derivatives under oxidative 
conditions behaved as in normoxia whereas reductive conditions mimicked hypoxic situation. The 
effect of the redox state in the amount of detectable hypoxia marker 6 h after incubation is, thus, 
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much higher than the effect of oxygen availability. The remaining MISO was detected at much higher 
concentration (33% of the TCho) for oxidative than reductive conditions (3% of the TCho) under 
normoxia (Figure 23b). Reducing oxygen availability induced a decrease from 15% in normoxia to 
12% and 11% in hypoxia and anoxia respectively (Figure 22b). Taken together, these results highlight 
the importance of the redox state in the reduction rate of nitroimidazolyl derivatives.  
Using EPR and EPRI, Kuppusamy et al (105) showed a preferential reduction of nitroxides in RIF-1 
tumors compared to normal tissue in mice. Furthermore, these authors showed that this increase 
was directly related to higher GSH concentration in tumor than in muscle. Using the GSH depletion 
agent BSO they demonstrated that the reduction rate of nitroxides is tightly coupled to reduced 
glutathione content in tumors. Previously, they demonstrated that these tumors present lower pO2 
(10 ± 2 mm Hg) than muscle (40 ± 2 mm Hg) and higher reducing capacity (104). Similar results were 
found by Yamada et al. (223). Depletion of GSH using diethylmaleate (DEM) decreased the reduction 
rate of nitroxides by 24% and 36% in normal and tumor (RIF-1) tissues respectively. This was linked to 
a reduction in GSH levels of 55% and 60% in tumor and muscle tissue respectively. On these grounds, 
the reason for the higher impact in tumor compared to normal tissue may be reflect the higher basal 
GSH levels in tumors. 
Several studies reported a relationship between nitroimidazolyl reduction and high levels of Non 
Protein Sulfhydryl groups (NPSH). Moreno-Merlo et al. (136) used cervical cancer xenografts (ME180 
and SiHa) grown in mice. They showed that areas with positive EF5 staining presented significantly 
higher levels of NPSH that those without EF5. Vukovic et al. (215) found differential expression of 
NPSH levels in regions of hypoxia, measured by EF5 staining, that are proximal or distal to blood 
vessels in cervical carcinoma xenografts tumors (SiHa cell line). Regions positively stained for EF5 
were classified by distance to the nearest visible blood vessel. Significantly higher NPSH levels were 
found in EF5 positive regions close to blood vessels than in regions at a higher distance from them. 
These results were explained through the assumption that regions distal from blood vessels 
presented impaired cellular metabolic status. Thus, increase in GSH consumption cannot be 
counterbalanced by the regeneration mechanism of GSH, resulting in a net loss. On the other hand, 
EF5 positive regions close to blood vessel are indeed intermittently perfused, and thus NPSH levels 
could be regenerated after transient hypoxia and the concomitant increase in GSH consumption.  
On these grounds, we proposed that the nitroimidazole reduction rate and subsequent binding to 
cellular components is controlled not only by pO2, but more importantly by the redox state. The 
relative contribution of each one of these parameters must be evaluated for each hypoxia marker 
individually. Nevertheless, both factors appear to be closely related in vivo. Furthermore, there is 
increasing evidence for crosstalk between hypoxia sensitivity and redox response pathways, mainly 
through the transcription factors HIF-1D and NF-NB (69). It is widely accepted that hypoxia increase 
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the production of reactive oxygen species (ROS) (37,38,45,46,118), while ROS promote the 
stabilization and activity of HIF-1D (7,8,38,118,182). 
Taken together, all these evidences suggest that oxygenation controls the reduction rate of 
nitroimidazolyl probes through the modulation of the redox state of the cell rather than through a 
direct effect on the reduction rate of these compounds.  
 5.1.4. Maps of in vivo bioreduction of 2-nitroimidazole derivatives 
 
Finally, we aimed to investigate whether nitroimidazolyl derivatives can be used as hypoxia marker in 
vivo in combination with 1H MRS detection. Previously, fluorinated nitroimidazole has been used for 
this purpose (157). This approach generates excellent signal to noise spectra due to absence of 
natural abundance fluorine signal. By using 1H MRS, metabolic information could be obtained at the 
same time, but the large amount of background resonances could difficult the detection. However, 
heterocyclic protons of nitroimidazole derivatives appear between 7.2 and 7.7 ppm, a spectral region 
where no resonances from other metabolites are usually detected, therefore overcoming this 
limitation.  
We used a similar approach to that described previously for fluorinated nitroimidazoles. We 
measured the MISO and TSP signal immediately after intratumoral injection and 60 min post 
injection, and their ratio was calculated. Due to the direct intratumoral injection of the probes, these 
were rapidly distributed within the tumor. The first measurement was considered as reflecting the 
total parental compound injected. The TSP decrease would provide a measurement of the natural 
clearance. We detected a tendency towards faster TSP clearance with decreasing oxygen availability 
(Table 8), although it did not reach statistical significance. Notably, MISO depicted a much larger 
decrease when diminishing the percentage of oxygen breathed. There was an increasing difference 
between the amount of remaining compound 1 h after injection between MISO and TSP with 
increasing hypoxia (Table 8). Both percentages were very similar in hyperoxia ([TSP]-[MISO]=6%), but 
this difference increased significantly in normoxia (15%). Moreover, during hypoxia, the difference 
between the remaining TSP and MISO reached his maximum value (24%). These results suggest that 
the main source of compound disappearance under hyperoxia is the physiological clearance, but 
under hypoxia, the biomarker reduction plays a dominant role in signal decrease. These results 
demonstrate that the new methodology is sensitive enough to detect changes in tumor oxygenation 
in vivo.  
We also show that real time imaging of the distribution of MISO and TSP is possible using multivoxel 
spectroscopy. Spectroscopic maps of the percentage of remaining MISO and TSP showed high 
intratumoral variability both for MISO and TSP in all animals investigated (Figures 27 and 28). 
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However, hyperoxygenated animals showed significantly higher percentage of remaining MISO (77 ± 
1 %) than normoxic animals (58 ± 1%). It should be noted that, there is not such difference for 
remaining TSP, which showed 72 ± 2 and 72 ± 1 % for hyperoxic and normoxic tumors, respectively.   
The approach proposed here presents several advantages over the previous studies. The use of 1H 
MRSI would allow obtaining metabolic and/or pH maps the region of interest. It presents, however, 
several drawbacks, as the high background signal from natural components of the imaged tissue. This 
prompted us to use larger doses (300 mg/kg) that previously described for 19F nitroimidazole (200 
mg/kg) (169), which afforded us also improved spatial (4 µl3) and temporal (12 min) resolution. Even 
with this higher dose, animals did not show any visible symptoms of toxicity. One of the main 
advantages of this approach relays in its direct and convenient translation to clinic, especially for 
tumors located superficially, as lymph nodes from head and neck tumors, where hypoxia has been 
demonstrated to become particularly relevant (6,29,86). Taken together, these results support the 
use of nitroimidazolyl derivatives as 1H MRS hypoxia sensitive probes. 
 
5.2 DOCENT (Dynamic Oxygen Challenge Evaluated by NMR T1 and T2*) 
 
In many cases, the selection of patients responding positively to hypoxia-directed treatments would 
not necessarily require a quantitative measurement of the oxygen tension but rather to monitor the 
response of tumors to a specific pO2 modulation. To this end, we implemented a novel imaging 
approach with high temporal and spatial resolution and using endogenous sources of contrast. This 
method is based on the paramagnetic properties of molecular oxygen (TOLD) and deoxyhemoglobin 
(BOLD) as surrogate markers of pO2. 
5.2.1. Predictive value of BOLD and TOLD to identify tumors responsive to pO2 
modulation  
 
As expected, BOLD and TOLD contrast responses to breathing hyperoxic gas were quite different for 
the diverse tumor sublines and sizes employed. Smaller HI tumors, reported to be well oxygenated 
and highly responsive to hyperoxic gas challenge (226), showed the largest signal changes, whereas 
larger AT1 tumors, reported to be hypoxic and unresponsive (25), showed the smallest responses. 
Each tumor showed considerable heterogeneity within an image slice, but quite similar response 
between slices and overall consistency between multiple tumors of a given group. 
BOLD signal responses were larger than TOLD using the current acquisition parameters (Figure 34), 
but there was a strong correlation between the magnitudes of both (Figure 35a). There was generally 
an inverse relationship between the magnitude of BOLD signal response and change in R2*, but direct 
correlation was weak (R2 = 0.6). This finding suggests additional effects beyond deoxyhemoglobin 
concentration influencing the SI (83). Indeed, carbogen breathing has been reported to increase both 
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oxyhemoglobin and total hemoglobin, as observed using near infrared spectroscopy of small HI 
tumors (113).  
The fact that the BOLD response is generally greater than the TOLD response prompts the question 
as to the advantage of measuring both parameters. A particular concern with BOLD alone is that it is 
subject to additional influences such as flow (83) and has been shown to exhibit contradictory 
behavior with respect to tumor oxygenation in some cases (83,89). Noting that BOLD responses 
preceded TOLD (Figures 29-32 & 34) adds confidence to the oxygen dependence, since enhanced 
oxygen delivery generates elevated pO2. Moreover, in HI tumors a strong correlation was found 
ďĞƚǁĞĞŶ ȴZ1 ĂŶĚ ȴZ2* consistent with change in vascular oxygenation underlying the change in 
tumor pO2, although this was not observed in the AT1 tumors (Figure 34b). BOLD alone showed 
significant differences between smaller HI tumors and smaller or larger AT1 tumors (Table 8). TOLD 
additionally showed a significant difference between the responses of larger HI and AT1 tumors. As a 
potential predictive biomarker, BOLD alone correctly characterized all the larger AT1 tumors as likely 
to be hypoxic (Table 10). However, BOLD misclassified 8 of 22 tumors expected to be oxic as hypoxic. 
TOLD alone misclassified only three of these tumors, suggesting that combined BOLD and TOLD 
stratification may be more robust. The large BOLD and TOLD responses in the HI tumors as compared 
with AT1 tumors were expected, since the HI tumors are reported to be much better vascularized 
and grow more slowly (227,228). 
5.2.2. Origin of BOLD and TOLD signals 
 
The T2*W signal response was very similar to that reported previously for AT1 tumors (87) and 
baseline R2* values fell within the range reported for diverse tumors types at 4.7 T (10,130,175,176). 
Human prostate tumors in patients and DU145 and PC3 tumor xenografts in mice were reported to 
have R2* values and signal responses similar to the R3327-AT1 and HI tumors found here (10). A 
return to baseline R2* before return to air breathing was reported in PC3 tumors, as seen for the 
larger AT1 tumors here (Figure 32c). 
Rodrigues et al. (176) pƌĞǀŝŽƵƐůǇƌĞƉŽƌƚĞĚƚŚĂƚȴZ2* in response to breathing carbogen was indicative 
of tumor growth delay in response to radiotherapy, in highly vascularized GH3 prolactinomas, but 
not in RIF-1 tumors. RIF-1 showed particularly low baseline R2* and little response to carbogen, 
consistent with small vascular fraction. Likewise, larger AT1 tumors, which are reported to exhibit 
large hypoxic fraction, which does not respond to hyperoxic gas breathing, showed the smallest 
BOLD signal response (Table 8). The larger AT1 tumors showed a tendency for increases in R2* with 
CB, as opposed to the other groups of tumors, which showed decreased values (Table 9). R1 values 
were in the range reported for many other tumor types at 4.7 T (131), though much lower than those 
reported for SCC tumors in a study of hyperoxic and hyperbaric gas intervention (125). 
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The T2*W measurements agree with independent reported oximetry both for HI and AT1 tumors, 
and hence, may become useful as non-invasive prognostic biomarkers to assess hypoxia, and predict 
response to hyperoxic gas breathing interventions. Indeed, in a previous study in rat breast tumors, it 
was shown that a BOLD signal response exceeding 3% coincided with elimination of hypoxic fraction 
(HF10< 5%) (230). A recent study by Arias-Ramos et al. (12) showed the predictive value of this 
technique. They used a C6 glioblastoma model implanted in rat brain and treated with radiotherapy 
in combination with hyperoxic gas breathing. The authors showed that tumors depicting diferences 
in TOLD response between tumoral and normal tissue bigger than 40% respond well to treatment 
combination whereas those with smaller changes showed no additional benefit to the animals 
treated in normoxic conditions. T2*W measurements alone are subjected to additional influences as 
ďůŽǁĨůŽǁ ?ŚĞŵŽŐůŽďŝŶĐŽŶƚĞŶƚ ?dhus adding T1W imaging protocols appears valuable.  
In summary, this new methodology is non-invasive, simple to implement, highly reproducible and 
reveals spatial and temporal heterogeneity of oxygen dynamics. Change in SI alone appears useful in 
itself, but we recognize its absolute magnitude depends on R1 and R2*, and the TE and TR times. Our 
results showed similar tumor stratification to that reported using quantitative 19F oximetry. Tumor 
stratification (oxic- responsive to oxygen breathing vs. hypoxic) may allow therapy to be tailored to 
the individual characteristics of the tumor.  
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1. We investigated the synthesis and the redox properties of a new series of nitroimidazole succinic 
esters, potentially useful as hypoxia probes. Dimethyl 2-nitroimidazol-1-ylsuccinate (NISUCA) 
depicted suitable properties, prompting their use as a novel 1H-MR hypoxia markers.  
2. The role of oxygen and GSH availability in the reduction of four nitroimidazole derivatives was 
tested. GSH showed to have a much greater impact than molecular oxygen in the reduction rate, 
increasing it either in anoxic and normoxic conditions. The influence of oxygen deprivation in the 
in vitro reduction of these compounds was negligible.  
3. We propose a new mechanism for the reduction of nitroimidazolyl derivatives. Within this new 
scheme, the control point in the reduction rate would be the covalent binding of the nitroso 
derivative, enzymatically generated, to GSH. This process would continue through the non 
enzymatic reduction of nitroso to hydroxylamine with concomitant oxidation of GSH to GSSG. 
Further reduction steps could occur either enzymatically of through the formation of new 
nitroimidazole-GSH adducts. The possible structures of these adducts are proposed. 
4. The potential use of nitroimidazole derivatives as hypoxia marker by 1H-MRS was investigated. 
All the compounds showed a greater decrease in the signal of initial concentration when 
incubated under hypoxic conditions than in normoxia, suggesting increased metabolism under 
hypoxic conditions. Nitroimidazolyl derivatives with higher in vitro reduction rate constants were 
more rapidly reduced ex vivo by C6 cells than those with slower in vitro reduction rate constants. 
5. Ex vivo studies showed that the redox state of the cell depicted a larger impact than the oxygen 
tension in the reduction of nitroimidazole derivative. Highly reductive environment (high GSH 
concentrations) resulted in faster consumption of the hypoxia probe than hypoxic environment, 
whereas highly oxidative environment (low GSH concentration) resulted in slower depletion of 
the hypoxia probe than normoxic conditions.  
6. We propose that the reduction of nitroimidazole derivative is not a direct measurement of pO2 
but of the associated changes in the redox state. Thus the in vivo selective reduction and 
retention of nitroimidazolyl derivatives is not a direct consequence of hypoxia but of the shift of 
the redox state towards a more reduced environment, resulting in faster reduction rates and 
increased retention of the biomarkers. Any other alteration of the redox environment not related 
to oxygen availability would eventually cause changes in the metabolism of 2-nitroimidazolyl 
derivatives.  
7. A new methodology for the use of 2-nitroimidazole derivatives as in vivo 1H-MRS hypoxia marker 
was described. It was based on the ratio of the hypoxia marker signal immediately after and 1 h 
after compound administration. This ratio was related to the percentage of oxygen in the 
inspired gas and these differences came from in vivo reduction of the hypoxia probe. 
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8. Dynamic Oxygen Challenge Evaluated by MR T1 and T2* (DOCENT) provided a non-invasive 
method to distinguish between responsive and non responsive tumors to hyperoxic gas 
challenge, potentially allowing hypoxic tumor identification and tailor therapy to these 
characteristics. 
9. DOCENT methodology is non-invasive, simple to implement, highly reproducible and reveals 
spatial and temporal heterogeneity of oxygen dynamics. It does not quantify pO2 or hypoxic 
fraction (potential advantages of 19F oximetry, ESR, or electrodes) but requires no exogenous 
reporter molecule and it is directly and easily translatable to the clinic. 
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